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CTGCAGCGTGCCCAGCTGTTCGTGGTGGTGATCGCGC~CGCGCTG~~CCGTCGC~TC 
GCCGCCGCCGGGCCGATCGAGTTCGTCGCCTTCGTCGTGCCGCA~AT~CCCTGC~CTC 
TGCGGCGGCAGCCGGCCGCCCCTGCTCGCCTCGGCGATGCTC~CGCGCTGCT~T~TC 
G G C G C C G A C C T G G T C G C T C A G A T C G T G G T G G C G C C G A A G G C T C  
ACCGCGATGATCGGCACCCCGTACCTGCTCTGGCTCCTGCTTC~CGATC~G~GGTG 
AGCGGATGAACGCCCGCCTGCGTGGCGAGGGCCTGCACCTC~GTACGGGGACCTGAC~G 
TGATCGACGGCCTCGACGTCGACGTGCACGACGGGCTGGTCACCACCATCATCGGGCCCA 
ACGGGTGCGGCAAGTCGACGCTGCTCAAGGCGCTCGGCCGCCCGACCGGCG 
GGCAGGTGCTGCTGGACGGCCGCCGCATCGACCGGACCCCCACCC~TGA~TGGCCCGGG 
T G C T C G G C G T G C T G C C G C A G T C G C C C A C C G C G C C C G A A G G C G A C C T G G  
T G A T G C G C G G C C G G C A C C C G C A C C A G A C C T G G T T C C G G C A G G  
ACCAGGTCGCCGACGCGCTGCGCTGGACCGACATGCTGGCGTACGCGGACCCGGTOG 
A C G C C C T C T C C G G C G G T C A G C G C C A G C G C G C C T G G A T C A G C A  
CCGACCTGCTGCTGCTGGACGAGCCGACCACCTTCCTCGACCTGGCCCACCAGATCGACG 
T G C T G G A C C T G G T C C G C C G G C T G C A C G C C G A G A T G G G C C G C T G C  
ACGACCTGAGCCTGGCCGCCCGGTACGCCGACCGGCTGATCGCGATG~~AC~CC~A 
TCGTGGCGAGCGGGGCGCCGGACGAGGTGCTCACCCCCG~GCTGCTGGAG~~GTCTTCG 
G G C T G C G C G C G A T G G T G G T G C C C G A C C C G G C G A C C G G C A T C C C C C T G C  
CGCGCCCCGCCACCTCGGTGCGGGCCTGAAATCGATGATGAGCGT~TTGCTTCATCGGCCTG 
CCGAGCGATGAGAGTATGTGGGCGGTAGAGCGAGTCTCGAG~~AGATGCCGCCGTGAC 
V T  
GTCCTCGTACATGCGCCTGAGCAGCAGCGATCGCCTTCGGTGTGATCGT~CGACCGC 
S S Y M R L K A A A I A F G V I V A T A  
1261 AGCCGTGCCGTCACCCGCTTCCGGCAGGGAACATGACQGCGGCTATGCG~CCTGATCCG 
23 A V P S P A S G R E H D G G Y A A L I R  
1321 CCGGGCCTCGTACGGCGTCCCGCACATCACCGCCGACGACGACTTCGGGAGCCTC~TTTCGG 
43 R A S Y G V P H I T A D D F G S L G F G  
1381 CGTCGGGTACGTGCAGGCCGAGGACAACATCTGCGTCATCTGC~TCATCGC~GAGAGCGTAGTGACGGC 
63 V G Y V Q A E D N I C V I A E S V V T A  
1441 CAACGGTGAGCGGTCGCGGTGGTTCGGTGCGACCGGGCCGGAC~ACGC~GATGT~G~AG 
83 N G E R S R W F G A T G P D D A D V R S  
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1501 CGACCTCTTCCACCGCAAGGCGATCGACGACCGCGTCGCCGAGCGGCTCCTCG~GGGCC 
103 D L  F H R  K A  I D D R V A E R  L L E G P 
1561 CCGCGACGGCGTGCGGGCGCCGTCGGACGACGTCCGGGACCAGATGCGCGGCTTCGTCGC 
123 R D G V R A P S D D V R D Q M R G F V A 
1621 CGGCTACAACCACTTCCTACGCCGCACCGGCGTGCACCGCCTGACCGACCCGGCGTGCCG 
143 G Y N H F L R R T G V H R L T D P A C R 
1681 CGGCAAGGCCTGGGTGCGCCCGCTCTCCGAGATCGATCTCTGGCGTACGTCGTGGGACAG 
163 G K A W V R P L S E I D L W R T S W D S 
1741 CATGGTCCGGGCCGGTTCCGGGGCGCTGCTCGACGGCATCGTCGCCGCGACGCCACCTAC 
183 M V R A G S G A L L D G I V A A T P P T 
1801 AGCCGCCGGGCCCGCGTCAGCCCCGGAGGCACCCGACGCCGCCGCGATCGCCGCCGCCCT 
203 A A G  P A S A  P E A P D A A A  I A A A L  
1861 CGACGGGACGAGCGCGGGCATCGGCAGCAACGCGCGTACGGCCTCGGCGCGCAGGCCACCGT 
223 D G T S A G I G S N A Y G L G A Q A T V 
1921 GAACGGCAGCGGGATGGTGCTGGCCAACCCGCACTTCCCGTGGCAGGGCGCCGCACGCTT 
243 N G S G M V L A N P H F P W Q G A A R F 
1981 CTACCGGATGCACCTCAAGGTGCCCGGCCGCTACGACGTCGAGGGCGCGGCGCTGATCGG 
263 Y R M H L K V P G R Y D V E G A A L I G 
2041 CGACCCGATCATCGGGATCGGGCACAACCGCACGGTCGCCTGGAGCCACACCGTCTCCAC 
283 D P I I G I G H N R T V A W S H T V S T  
2101 CGCCCGCCGGTTCGTGTGGCACCGCCTGAGCCTCGTGCCCGGCGACCCCACCTCCTATTA 
303 A R R F V W H R L S L V P G D P T S Y Y 
2161 CGTCGACGGCCGGCCCGAGCGGATGCGCGCCCGCACGGTCACGGTCCAGACCGGCAGCGG 
323 V D G R P E R M R A R T V T V Q T G S G 
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2 2 2 1  CCCGGTCAGCCGCACCTTCCACGACACCCGCTACGGCCCGPvTGGCCGTGATGCCGGGCAC 
343 P V S R T F H D T R Y G P V A V M P G T  
2 2 8 1  CTTCGACTGGACGCCGGCCACCGCGTACGCCATCACCGACGTC~CGCGGGC~C~CCG 
363 F D W T P A T A Y A I T D V N A G N N R 
2 3 4 1  C G C C T T C G A C G G G T G G C T G C G G A T G G G G C C A A G G A C C G G T  
383 A F D G W L R M G Q A K D V R A L  K A V  
2 4 0 1  C C T C G A C C G G C A C C A G T T C C T G C C C T G G G T C A A C G T G A T C ~ G G G G C G A  
4 0 3  L D R H Q F L  P W V N V  I A A D A R G E  
2 4 6 1  GGCCCTCTACGGCGATCATTCGGTCGTCCCCCGGGTGACCGGCGCGC~GCTGCCGCCTG 
4 2 3  A L Y G D H S V V P R V T G A L A A A C 
2521 CATCCCGGCGCCGTTCCAGCCGCTCTACGCCTCCAGCGGCCAGGCGGTCCTGGAC~TTC 
4 4 3  I P A P F Q P L Y A S S G Q A V L D G S 
2 5 8 1  CCGGTCGGACTGCGCGCTCGCGCCGACCCCGACGCCGCGGTCCCGGGCATTCTC~GCCC 
4 6 3  R S D C A L G A D P D A A V P G I  L G P  
2 6 4 1  GGCGAGCCTGCCGGTGCGGTTCCGCGACGACTACGTCACCAACTCC~CGACAGTCACTG 
4 8 3  A S L P V R F R D D Y V T N S N D S H W 
2 7 0 1  GCTGGCCAGCCCGGCCGCCCCGCTGGAAGGCTTCCCGCTTCCCGC~ATCCTCGC~CG~CGCAC 
503 L A S P A A P L E G F P R I L G N E R T 
2 7 6 1  CCCGCGCAGCCTGCGCACCCGGCTCGGGCTGGACCAGACCAGATCCAGCAGCGCCTC~CGGCAC 
5 2 3  P R S L R T R L G L D Q I Q Q R L A G T 
2 8 2 1  G G A C G G T C T G C C C G G C A A G G G C T T C A C C A C C G C C C G G C T C  
543 D G  L P G  K G  F T T A R L  W Q V M  F G N  
2 8 8 1  CCGGATGCACGGCGCCGAACTC~CCGCGACGACGA~CTGGTCGCGCTCTG~CGCCGCCAGCC 
563 R M H G A E L A R D D L V A L C R R Q P 
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2 9 4 1  G A C C G C G A C C G C C T C G A A C G G C G C G A T C G T C G A C C T C A C C ~ ~ C C ~ C A C ~ G ~ ~ T C  
5 8 3  T A T A S N G A  I V D L T A A C T A L S  
3 0 0 1  CCGCTTCGATGAGCGTGCCGACCTGGACAGCCGGGGCGCGCACCTGTTCACCGAGTTCGC 
6 0 3  R F D E R A D L D S R G A H L F T E F A 
3 0 6 1  CCTCGCGGGCGGAATCAGGTTCGCCGACACCTTCGAGGTGACCGAT~CGGTACGCACCCC 
6 2 3  L A G G I R F A D T F E V T D P V R T P 
3 1 2 1  GCGCCGTCTGAACACCACGGATCCGCGGGGTACGGACGG~CT~CGA~CCGTGCAACG 
6 4 3  R R L N T T D P R V R T A L A D A V Q R 
3181 GCTCGCCGGCATCCCCCTCGACGCGAAGCTGGGAGACATC~ACACCGA~GCCGCGGCGA 
6 6 3  L A G I P L I) A K L G D I H T D S R G E 
3 2 4 1  ACGGCGCATCCCCATCCACGGTGGCCGCGGGGAAG~GGCACCTTC~CGTGATCACCAA 
6 8 3  R R I P I H G G R G E A G T F N V I T N 
3301 CCCGCTCGTGCCGGGCGTGGGATACCCGCAGGTCGTCCACGG~CATCGT~CGTGA~GC 
7 0 3  P L V P G V G Y P Q V V H G T S F V M A 
3 3 6 1  CGTCGAACTCGGCCCGCACGGCCCGTCGGGACGGCAGAT~CTCACCTATGCGCAGTCGAC 
7 2 3  V E L G  P H G  P S G R Q  I L T Y A Q S  T 
3 4 2 1  GAACCCGAACTCACCCTGGTACGCCGACCAGACCGTGCTCTACTCGC~AAG~CTG~A 
7 4 3  N P N S P W Y A D Q T V L Y S R K G W D 
3481 CACCATCAAGTACACCGAGGCGCAGATCGCGGCCGACCGACCCG~CCTGCGCGTCTACCGGGT 
7 6 3  T I  K Y T E A Q I A A D P N L R V Y R V  
3 5 4 1  G G C A C A G C G G G G A C G C T G A C C C A C G T C A C G C C G G C T C G G C G G C G  
7 8 3  A Q R G R *  
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CCGATCGTCTCTGCATCGCCGGTCAGCCGGGGCCGGGGCCTGCGTCGACCGGCGGC~CC~TCGA 
CGCCCGCGTCCCGGCGCAGCGACTGGCTGAAGCGCGCCAGGCGTCG~CGGCCC~GGCAGGT 
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METHOD FOR CREATING 
POLYNUCLEOTIDE AND POLYPEPTIDE 
SEQUENCES 
CROSS-REFERENCES TO RELATED 
APPLICATIONS 
This application derives priority from U.S. Ser. No. 
601067,908, filed Dec. 8, 1997, which is incorporated by 
reference in its entirety for all purposes. 
STATEMENT OF GOVERNMENT INTEREST 
The invention described herein was made in the perfor- 
mance of work under a NASA contract, and is subject to the 
provisions of Public Law 96-517 (35 USC 9202) in which 
the contractor has elected to retain title. 
COPYRIGHT NOTICE 
A portion of the disclosure of this patent document 
contains material which is subject to copyright protection. 
The copyright owner has no objection to the facsimile 
reproduction by anyone of the patent document or the patent 
disclosure as it appears in the Patent and Trademark Office 
patent file or records, but otherwise reserves all copyright 
rights whatsoever. 
TECHNICAL FIELD 
The invention resides in the technical field of genetics, 
and more specifically, forced molecular evolution of poly- 
nucleotides to acquire desired properties. 
BACKGROUND 
A variety of approaches, including rational design and 
directed evolution, have been used to optimize protein 
functions (1, 2). The choice of approach for a given opti- 
mization problem depends, in part, on the degree of under- 
standing of the relationships between sequence, structure 
and function. Rational redesign typically requires extensive 
knowledge of a structure-function relationship. Directed 
evolution requires little or no specific knowledge about 
structure-function relationship; rather, the essential features 
is a means to evaluate the function to be optimized. Directed 
evolution involves the generation of libraries of mutant 
molecules followed by selection or screening for the desired 
function. Gene products which show improvement with 
respect to the desired property or set of properties are 
identified by selection or screening. The gene(s) encoding 
those products can be subjected to further cycles of the 
process in order to accumulate beneficial mutations. This 
evolution can involve few or many generations, depending 
on how far one wishes to progress and the effects of 
mutations typically observed in each generation. Such 
approaches have been used to create novel functional 
nucleic acids (3, 4), peptides and other small molecules (3), 
antibodies (3), as well as enzymes and other proteins (5, 6, 
7). These procedures are fairly tolerant to inaccuracies and 
noise in the function evaluation (7). 
Several publications have discussed the role of gene 
recombination in directed evolution (see WO 97107205, WO 
98142727, U.S. Pat. No. 5,807,723, U.S. Pat. No. 5,721,367, 
U.S. Pat, No. 5,776,744 and WO 98141645 U.S. Pat. No. 
5,811,238, WO 98141622, WO 98141623, and U.S. Pat. No. 
5,093,257). 
APCR-based group of recombination methods consists of 
DNA shuffling [5, 61, staggered extension process [89, 901 
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and random-priming recombination [87]. Such methods 
typically involve synthesis of significant amounts of DNA 
during assemblyirecombination step and subsequent ampli- 
fication of the final products and the efficiency of amplifi- 
cation decreases with gene size increase. 
Yeast cells, which possess an-active system for homolo- 
gous recombination, have been used for in vivo recombina- 
tion. Cells transformed with a vector and partially overlap- 
ping inserts efficiently join the inserts together in the regions 
of homology and restore a functional, covalently-closed 
plasmid [91]. This method does not require PCR amplifica- 
tion at any stage of recombination and therefore is free from 
the size considerations inherent in this method. However, the 
number of crossovers introduced in one recombination event 
is limited by the efficiency of transformation of one cell with 
multiple inserts. Other in vivo recombination methods entail 
recombination between two parental genes cloned on the 
same plasmid in a tandem orientation. One method relies on 
homologous recombination machinery of bacterial cells to 
produce chimeric genes [92]. A first gene in the tandem 
provides the N-terminal part of the target protein, and a 
second provides the C-terminal part. However, only one 
crossover can be generated by this approach. Another in vivo 
recombination method uses the same tandem organization of 
substrates in a vector [93]. Before transformation into E. coli 
cells, plasmids are linearized by endonuclease digestion 
between the parental sequences. Recombination is per- 
formed in vivo by the enzymes responsible for double-strand 
break repair. The ends of linear molecules are degraded by 
a 5"3' exonuclease activity, followed by annealing of 
complementary single-strand 3' ends and restoration of the 
double-strand plasmid [94]. This method has similar advan- 
tages and disadvantages of tandem recombination on circu- 
lar plasmid. 
SUMMARY OF THE INVENTION 
The invention provides methods for evolving a polynucle- 
otide toward acquisition of a desired property. Such methods 
entail incubating a population of parental polynucleotide 
variants under conditions to generate annealed polynucle- 
otides comprises heteroduplexes. The heteroduplexes are 
then exposed to a cellular DNA repair system to convert the 
heteroduplexes to parental polynucleotide variants or 
recombined polynucleotide variants. The resulting poly- 
nucleotides are then screened or selected for the desired 
property. 
In some methods, the heteroduplexes are exposed to a 
DNA repair system in vitro. A suitable repair system can be 
prepared in the form of cellular extracts. 
In other methods, the products of annealing including 
heteroduplexes are introduced into host cells. The hetero- 
duplexes are thus exposed to the host cells' DNA repair 
system in vivo. 
In several methods, the introduction of annealed products 
into host cells selects for heteroduplexes relative to trans- 
formed cells comprising homoduplexes. Such can be 
achieved, for example, by providing a first polynucleotide 
variant as a component of a first vector, and a second 
polynucleotide variant is provided as a component of a 
second vector. The first and second vectors are converted to 
linearized forms in which the first and second polynucle- 
otide variants occur at opposite ends. In the incubating step, 
single-stranded forms of the first linearized vector reanneal 
with each other to form linear first vector, single-stranded 
forms of the second linearized vector reanneal with each 
other to form linear second vector, and single-stranded 
3 
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linearized forms of the first and second vectors anneal with 
each to form a circular heteroduplex bearing a nick in each 
strand. Introduction of the products into cells thus selects for 
cirular heteroduplexes relative to the linear first and second 
vector. Optionally, in the above methods, the first and second 
vectors can be converted to linearized forms by PCR. 
Alternatively, the first and second vectors can be converted 
to linearized forms by digestion with first and second 
restriction enzymes. 
In some methods, polynucleotide variants are provided in 
double stranded form and are converted to single stranded 
form before the annealing step. Optionally, such conversion 
is by conducting asymmetric amplification of the first and 
second double stranded polynucleotide variants to amplify a 
first strand of the first polynucleotide variant, and a second 
strand of the second polynucleotide variant. The first and 
second strands anneal in the incubating step to form a 
heteroduplex. 
In some methods, a population of polynucleotides com- 
prising first and second polynucleotides is provided in 
double stranded form, and the method further comprises 
incorporating the first and second polynucleotides as com- 
ponents of first and second vectors, whereby the first and 
second polynucleotides occupy opposite ends of the first and 
second vectors. In the incubating step single-stranded forms 
of the first linearized vector reanneal with each other to form 
linear first vector, single-stranded forms of the second 
linearized vector reanneal with each other to form linear 
second vector, and single-stranded linearized forms of the 
first and second vectors anneal with each to form a circular 
heteroduplex bearing a nick in each strand. In the introduc- 
ing step selects for transformed cells comprises the circular 
heteroduplexes relative to the linear first and second vector. 
In some methods, the first and second polynucleotides are 
obtained from chromosomal DNA. In some methods, the 
polynucleotide variants encode variants of a polypeptide. In 
some methods, the population of polynucleotide variants 
comprises at least 20 variants. In some methods, the popu- 
lation of polynucleotide variants are at least 10 kb in length. 
In some methods, the polynucleotide variants comprises 
natural variants. In other methods, the polynucleotide vari- 
ants comprise variants generated by mutagenic PCR or 
cassette mutagenesis. In some methods, the host cells into 
which heteroduplexes are introduced are bacterial cells. In 
some methods, the population of variant polynucleotide 
variants comprises at least 5 polynucleotides having at least 
90% sequence identity with one another. 
Some methods further comprise a step of at least partially 
demethylating variant polynucleotides. Demethylation can 
be achieved by PCR amplification or by passaging variants 
through methylation-deficient host cells. 
Some methods include a further step of sealing one or 
more nicks in heteroduplex molecules before exposing the 
heteroduplexes to a DNArepair system. Nicks can be sealed 
by treatment with DNA ligase. 
Some methods further comprise a step of isolating a 
screened recombinant polynucleotide ariant. In some 
methods, the polynucleotide variant is screened to produce 
a recombinant protein or a secondary metabolite whose 
production is catalyzed thereby. 
In some methods, the recombinant protein or secondary 
metabolite is formulated with a carrier to form a pharma- 
ceutical composition. 
In some methods, the polynucleotide variants encode 
enzymes selected from the group consisting of proteases, 
lipases, amylases, cutinases, cellulases, amylases, oxidases, 
peroxidases and phytases. In other methods, the polynucle- 
otide variants encode a polypeptide selected from the group 
consisting of insulin, ACTH, glucagon, somatostatin, 
somatotropin, thymosin, parathyroid hormone, pigmentary 
s hormones, somatomedin, erthropoietin, luteinizing 
hormone, chorionic gonadotropin, hyperthalmic releasing 
factors, antidiuretic hormones, thyroid stimulating hormone, 
relaxin, interferon, thrombopoietic (TPO), and prolactin. 
In some methods, each polynucleotide in the population 
10 of variant polynucleotides encodes a plurality of enzymes 
forming a metabolic pathway. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 illustrates the process of heteroduplex formation 
using polymerase chain reaction (PCR) with one set of 
primers for each different sequence to amplify the target 
sequence and vector. 
FIG. 2 illustrates the process of heteroduplex formation 
2o using restriction enzymes to linearize the target sequences 
and vector. 
FIG. 3 illustrates a process of heteroduplex formation 
using asymmetric or single primer polymerase chain reac- 
tion (PCR) with one set of primers for each different 
FIG. 4 illustrates heteroduplex recombination using 
unique restriction enzymes (X and Y) to remove the homo- 
duplexes. 
FIG. 5 shows the amino acid sequences of the FlaA from 
30 R. Zupini (SEQ ID NO: 1) and R. rneZiZoti (SEQ ID NO:2). 
FIG. 6 shows the locations of the unique restriction sites 
FIGS. 7A, B, C and D show the DNA sequences of four 
35 mosaic flaA genes created by in vitro heteroduplex forma- 
tion followed by in vivo repair ((a) is SEQ ID NO:3, (b) is 
SEQ ID NO:4, (c) is SEQ ID NO:5 and (d) is SEQ ID NO:6). 
FIG. 8 illustrates how the heteroduplex repair process 
created mosaic flaA genes containing sequence information 
FIG. 9 shows the physical maps ofActinopZunes utuhensis 
ECB deacylase mutants with enhanced specific activity ((a) 
is pM7-2 for Mutant 7-2, and (b) is pM16 for Mutant 16). 
FIG. 10  illustrates the process used for Example 2 to 
45 recombine mutations in Mutant 7-2 and Mutant 16 to yield 
ECB deacylase recombinant with more enhanced specific 
activity. 
FIG. 11 Specific activities of wild-type ECB deacylase 
and improved mutants Mutant 7-2, Mutant 16 and recom- 
bined Mutant 15. 
FIG. 12. Positions of DNA base changes and amino acid 
substitutions in recombined ECB deacylase Mutant 15 with 
respect to parental sequences of Mutant 7-2 and Mutant 16. 
FIGS. 13A, B, C, D and E show the DNA sequence of 
A.utuhensis ECB deacylase gene mutant M-15 genes created 
by in vitro heteroduplex formation followed by in vivo 
repair (SEQ ID NO:7). 
FIG. 14  illustrates the process used for Example 3 to 
60 recombine mutations in RC1 and RC2 to yield thermostable 
subtilisin E. 
FIG. 15 illustrates the sequences of RC1 and RC2 and the 
ten clones picked randomly from the transformants of the 
reaction products of duplex formation as described in 
65 Example 3. The x’s correspond to base positions that differ 
between RC1 and RC2. The mutation at 995 corresponds to 
amino acid substitution at 181, while that at 1107 corre- 
15 
2s sequence to amplify the target sequence and vector. 
utilized to linearize pRL20 and pRM40. 
40 from both parent genes. 
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sponds to an amino acid substitution at 218 in the subtilisin 
protein sequence. 
FIG. 16 shows the results of screening 400 clones from 
the library created by heteroduplex formation and repair for 
initial activity (A,) and residual activity (A,). The ratio A,/A,, 5 
was used to estimate the enzymes’ thermostability. Data 
from active variants are sorted and plotted in descending 
order. Approximately 12.9% of the clones exhibit a pheno- 
type corresponding to the double mutant containing both the 
N181D and the N218S mutations. 
aligning a comparison window can be conducted by com- 
puterized implementations of algorithms GAP, BESTFIT, 
FASTA, and TFASTA in the Wisconsin Genetics Software 
Package Release 7.0, Genetics Computer Group, 575 sei- 
The term naturally-occurring is used to describe an object 
that can be found in nature as distinct from being artificially 
produced by man. For example, a polypeptide or polynucle- 
otide sequence that is present in an organism (including 
10 viruses) that can be isolated from a source in nature and 
which has not been intentionally modified by man in the 
DEFINITIONS laboratory is naturally-occurring. Generally, the term 
Screening is, in general, a two-step process in which one naturally-occurring refers to an object as present in a non- 
first physically separates the cells and then determines which pathological (undiseased) individual, such as would be 
cells do and do not possess a desired property. Selection is typical for the species. 
a form of screening in which identification and physical A nucleic acid is operably linked when it is placed into a 
separation are achieved simultaneously by expression of a functional relationship with another nucleic acid sequence. 
selection marker, which, in some genetic circumstances, For instance, a promoter or enhancer is operably linked to a 
cells die (or vice versa). Exemplary screening members 2o coding sequence. Operably linked means that the DNA 
include luciferase, Bgalactosidase and green fluorescent sequences being linked are typically contiguous and, where 
genes. Although spontaneous selection can and does occur in reading frame. However, since enhancers generally func- 
in the course of natural evolution, in the present methods tion when separated from the promoter by several kilobases 
selection is performed by man. 25 and intronic sequences may be of variable lengths, some 
An exogenous DNA segment is one foreign (or polynucleotide elements may be operably linked but not 
heterologous) to the cell or homologous to the cell but in a contiguous. 
Dr., Madison, WiS. 
allows cells expressing the marker to survive while other coding sequence if it increases the transcription of the 
protein. Selection markers include drug and toxin resistance necessary to join two protein coding regions, contiguous and 
position within the host cell nucleic acid in which the A specific binding affinity between, for example, a ligand 
element is not ordinarily found. Exogenous DNA segments 3o and a receptor, means a binding affinity of at least 1 ~ 1 0 ~  
The term ‘‘cognate” as used herein refers to a gene 
are expressed to yield exogenous polypeptides. M-1. 
DNA associated with a biological function. Thus, genes sequence that is evolutionarily and functionally related 
include coding sequences and/or the regulatory sequences between species. For example but not limitation, in the 
required for their expression. Genes also include nonex- 35 human genome, the human CD4 gene is the cognate gene to 
Pressed DNA segments that, for example, form recognition the mouse CD4 gene, since the sequences and structures of 
sequences for other proteins. these two genes indicate that they are highly homologous 
The term “wild-type” means that the nucleic acid frag- and both genes encode a protein which functions in signal- 
ment does not comprise any mutations. A “wild-type” pro- ing T cell activation through MHC class 11-restricted antigen 
tein means that the protein will be active at a level of activity 4o recognition. 
found in nature and typically will comprise the amino acid The term “heteroduplex” refers to hybrid DNA generated 
sequence found in nature. In an aspect, the term ‘‘wild type” by base pairing between complementary single strands 
or “parental sequence” can indicate a starting or reference derived from the different parental duplex molecules, 
sequence prior to a manipulation of the invention. whereas the term “homoduplex” reters to double-stranded 
“Substantially pure” means an object species is the pre- 45 DNA generated by base pairing between complementary 
dominant species present (i.e., on a molar basis it is more single strands derived from the same parental duplex mol- 
abundant than any other individual macromolecular species ecules. 
in the composition), and preferably a substantially purified The term ‘‘nick” in duplex DNA refers to the absence of 
fraction is a composition wherein the object species com- a phosphodiester bond between two adjacent nucleotides on 
prises at least about 50 percent (on a molar basis) of all 50 one strand, The term “gap” in duplex DNA refers to an 
macromolecular species present. Generally, a substantially absence of one or more nucleotides in one strand of the 
pure composition will comprise more than about 80 to 90 duplex, The term “loop” in duplex DNA refers to one or 
percent of all macromolecular species present in the com- more unpaired nucleotides in one strand, 
position. Most preferably, the object species is purified to A mutant or variant sequence is a sequence showing 
essential homogeneity (contaminant species cannot be 55 substantial variation from a wild type or reference sequence 
detected in the composition by that differs from the wild type or reference sequence at one 
The term gene is used broadly to refer to any segment of 
detection 
methods) wherein the composition consists essentially of a or positions, 
single macromolecular species. Solvent species, small mol- 
ecules (e500 Daltons), and elemental ion species are not DETAILED DESCRIPTION 
I. General Percentage sequence identity is calculated by comparing 
two optimally aligned sequences over the window of The invention provides methods of evolving a polynucle- 
comparison, determining the number of positions at which otide toward acquisition of a desired property. The substrates 
the identical nucleic acid base occurs in both sequences to for the method are a population of at least two polynucle- 
yield the number of matched positions, dividing the number 65 otide variant sequences that contain regions of similarity 
of matched positions by the total number of positions in the with each other but, which also have point(s) or regions of 
window of comparison. Optimal alignment of sequences for divergence. The substrates are annealed in vitro at the 
considered macromolecular species. 60 
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regions of similarity. Annealing can regenerate initial sub- 
strates or can form heteroduplexes, in which component 
strands originate from different parents. The products of 
annealing are exposed to enzymes of a DNA repair, and 
optionally a replication system, that repairs unmatched 
pairings. Exposure can be in vivo as when annealed products 
are transformed into host cells and exposed to the hosts DNA 
repair system. Alternatively, exposure can be in vitro, as 
when annealed products are exposed to cellular extracts 
containing functional DNA repair systems. Exposure of 
heteroduplexes to a DNA repair system results in DNA 
repair at bulges in the heteroduplexes due to DNA mis- 
matching. The repair process differs from homologous 
recombination in promoting nonreciprocal exchange of 
diversity between strands. The DNA repair process is typi- 
cally effected on both component strands of a heteroduplex 
molecule and at any particular mismatch is typically random 
as to which strand is repaired. The resulting population can 
thus contain recombinant polynucleotides encompassing an 
essentially random reassortment of points of divergence 
between parental strands. The population of recombinant 
polynucleotides is then screened for acquisition of a desired 
property. The property can be a property of the polynucle- 
otide per se, such as capacity of a DNA molecule to bind to 
a protein or can be a property of an expression product 
thereof, such as mRNA or a protein. 
11. Substrates For Shuffling 
The substrates for shuffling are variants of a reference 
polynucleotide that show some region(s) of similarity with 
the reference and other region(s) or point(s) of divergence. 
Regions of similarity should be sufficient to support anneal- 
ing of polynucleotides such that stable heteroduplexes can 
be formed. Variants forms often show substantial sequence 
identity with each other (e.g., at least 50%, 75%, 90% or 
99%). There should be at least sufficient diversity between 
substrates that recombination can generate more diverse 
products than there are starting materials. Thus, there must 
be at least two substrates differing in at least two positions. 
The degree of diversity depends on the length of the sub- 
strate being recombined and the extent of the functional 
change to be evolved. Diversity at between 0.1-25% of 
positions is typical. Recombination of mutations from very 
closely related genes or even whole sections of sequences 
from more distantly related genes or sets of genes can 
enhance the rate of evolution and the acquisition of desirable 
new properties. Recombination to create chimeric or mosaic 
genes can be useful in order to combine desirable features of 
two or more parents into a single gene or set of genes, or to 
create novel functional features not found in the parents. The 
number of different substrates to be combined can vary 
widely in size from two to 10, 100, 1000, to more than lo5, 
lo7, or lo9 members. 
The initial small population of the specific nucleic acid 
sequences having mutations may be created by a number of 
different methods. Mutations may be created by error-prone 
PCR. Error-prone PCR uses low-fidelity polymerization 
conditions to introduce a low level of point mutations 
randomly over a long sequence. Alternatively, mutations can 
be introduced into the template polynucleotide by 
oligonucleotide-directed mutagenesis. In oligonucleotide- 
directed mutagenesis, a short sequence of the polynucleotide 
is removed from the polynucleotide using restriction enzyme 
digestion and is replaced with a synthetic polynucleotide in 
which various bases have been altered from the original 
sequence. The polynucleotide sequence can also be altered 
by chemical mutagenesis. Chemical mutagens include, for 
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example, sodium bisulfite, nitrous acid, hydroxylamine, 
hydrazine or formic acid. Other agents which are analogues 
of nucleotide precursors include nitrosoguanidine, 
5-bromouracil, 2-aminopurine, or acridine. Generally, these 
agents are added to the PCR reaction in place of the 
nucleotide precursor thereby mutating the sequence. Inter- 
calating agents such as proflavine, acriflavine, quinacrine 
and the like can also be used. Random mutagenesis of the 
polynucleotide sequence can also be achieved by irradiation 
with X-rays or ultraviolet light. Generally, plasmid DNA or 
DNA fragments so mutagenized are introduced into E. coli 
and propagated as a pool or library of mutant plasmids. 
Alternatively the small mixed population of specific 
nucleic acids can be found in nature in the form of different 
alleles of the same gene or the same gene from different 
related species (i.e., cognate genes). Alternatively, substrates 
can be related but nonallelic genes, such as the immunoglo- 
bulin genes. Diversity can also be the result of previous 
recombination or shuffling. Diversity can also result from 
resynthesizing genes encoding natural proteins with alter- 
native codon usage. 
The starting substrates encode variant forms of sequences 
to be evolved. In some methods, the substrates encode 
variant forms of a protein for which evolution of a new or 
modified property is desired. In other methods, the sub- 
strates can encode variant forms of a plurality of genes 
constituting a multigene pathway. In such methods, variation 
can occur in one or any number of the component genes. In 
other methods, substrates can contain variants segments to 
be evolved as DNAor RNA binding sequences. In methods, 
in which starting substrates containing coding sequences, 
any essential regulatory sequences, such as a promoter and 
polyadenylation sequence, required for expression may also 
be present as a component of the substrate. Alternatively, 
such regulatory sequences can be provided as components of 
vectors used for cloning the substrates. 
The starting substrates can vary in length from about 50, 
250, 1000, 10,000, 100,000, lo6 or more bases. The starting 
substrates can be provided in double- or single-stranded 
form. The starting substrates can be DNA or RNA and 
analogs thereof. If DNA, the starting substrates can be 
genomic or cDNA. If the substrates are RNA, the substrates 
are typically reverse-transcribed to cDNA before heterodu- 
plex formation. Substrates can be provided as cloned 
fragments, chemically synthesized fragments or PCR ampli- 
fication products. Substrates can derive from chromosomal, 
plasmid or viral sources. In some methods, substrates are 
provided in concatemeric form. 
111. Procedures for Generating Heteroduplexes 
Heteroduplexes are generated from double stranded DNA 
substrates, by denaturing the DNA substrates and incubating 
under annealing conditions. Hybridization conditions for 
heteroduplex formation are sequence-dependent and are 
different in different circumstances. Longer sequences 
hybridize specifically at higher temperatures. Generally, 
hybridization conditions are selected to be about 25" C. 
lower than the thermal melting point (Tm) for the specific 
sequence at a defined ionic strength and pH. The Tm is the 
temperature (under defined ionic strength, pH, and nucleic 
acid concentration) at which 50% of the probes complemen- 
tary to the target sequence hybridize to the target sequence 
at equilibrium. 
Exemplary conditions for denaturation and renaturation 
of double stranded substrates are as follows. Equimolar 
concentrations (-1.0-5.0 nM) of the substrates are mixed in 
US 6,537,746 B2 
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lxSSPE buffer (180 mM NaC1, 1.0 mM EDTA, 10 mM be subjected to amplification with amplification in each 
NaH,POQ, pH 7.4) After heating at 96" C. for 10 minutes, vector starting at a different point. For each substrate, this 
the reaction mixture is immediately cooled at 0" C. for 5 process generates amplification products varying in how 
minutes; The mixture is then incubated at 68" C. for 2-6 hr. flanking vector DNA is divided on the two sides of the 
Denaturation and reannealing can also be carried out by the 5 substrate. For example, one amplification product might 
addition and removal of a denaturant such as NaOH. The have most of the vector on one side of the substrate, another 
process is the same for single stranded DNA substrates, amplification product might have most of the vector on the 
except that the denaturing step may be omitted for short other side of the substrate, and a further amplification 
sequences. product might have an equal division of vector sequence 
By appropriate design of substrates for heteroduplex flanking the substrate. In the subsequent annealing step, a 
formation, it is possible to achieve selection for heterodu- strand of substrate can form a circular heteroduplex with a 
plexes relative to reformed parental homoduplexes. Homo- strand of any other substrate, but strands of the same 
duplexes merely reconstruct parental substrates and effec- substrate can only reanneal with each other to form a linear 
tively dilute recombinant products in subsequent screening homoduplex. In a still further variation, multiple substrates 
steps. In general, selection is achieved by designing sub- 15 can be performed by performing multiple iterations of the 
strates such that heteroduplexes are formed in open-circles, scheme in FIG. 1. After the first iteration, recombinant 
whereas homoduplexes are formed as linear molecules. A polynucleotides in a vector, undergo heteroduplex formation 
subsequent transformation step results in substantial enrich- with a third substrate incorporated into a further copy of the 
ment (e.g., 100-fold) for the circular heteroduplexes. vector. The vector bearing the recombinant polynucleotides 
FIG. 1 shows a method in which two substrate sequences 2o and the vector bearing the third substrate are separately PCR 
in separate vectors are PCR-amplified using two different amplified from different primer pairs. The amplification 
sets of primers (Pl,  P2 and P3, P4). Typically, first and products are then denatured and annealed. The process can 
second substrates are inserted into separate copies of the be repeated further times to allow recombination with fur- 
same vector. The two different pairs of primers initiate ther substrates. 
amplification at different points on the two vectors. FIG. 1 25 An alternative scheme for heteroduplex formation is 
shows an arrangement in which the P I P 2  primer pairs shown in FIG. 2. Here, first and second substrates are 
initiates amplification at one of the two boundaries of the incorporated into separate copies of a vector. The two copies 
vector with the substrate and the P1P2 primer pair initiates are then respectively digested with different restriction 
replication at the other boundary in a second vector. The two enzymes. FIG. 2 shows an arrangement in which, the 
primers in each primer pair prime amplification in opposite 30 restriction enzymes cut at opposite boundaries between 
directions around a circular plasmid. The amplification substrates and vector, but all that is necessary is to use two 
products generated by this amplification are double-stranded different restriction enzymes that cut at different places. 
linearized vector molecules in which the first and second Digestion generates linearized first and second vector bear- 
substrates occur at opposite ends of the vector. The ampli- ing first and second substrates, the first and second substrates 
fication products are mixed, denatured and annealed. Mixing 35 occupying different positions relative to the remaining vec- 
and denaturation can be performed in either order. Rean- tor sequences. Denaturation and reannealing generates open 
nealing generates two linear homoduplexes, and an open circular heteroduplexes and linear homoduplexes. The 
circular heteroduplex containing one nick in each strand, at scheme can be extended to recombination between more 
the initiation point of PCR amplification. Introduction of the than two substrates using analogous strategies to those 
amplification products into host cells selects for the hetero- 40 described with respect to FIG. 1. In one variation, two pools 
duplexes relative to the homoduplexes because the former of substrates are formed, and each is separately cloned into 
transform much more efficiently than the latter. vector. The two pools are then cute with different enzymes, 
It is not essential in the above scheme that amplification and annealing proceeds as for two substrates. In another 
is initiated at the interface between substrate and the rest of variation, three or more substrates can be cloned into three 
the vector. Rather, amplification can be initiated at any 45 or more copies of vector, and the three or more result 
points on two vectors bearing substrates provided that the molecules cut with three or more enzymes, cutting at three 
amplification is initiated at different points between the or more sites. This generates three different linearized vector 
vectors. In the general case, such amplification generates forms differing in the division of vector sequences flanking 
two linearized vectors in which the first and second sub- the substrate moiety in the vectors. Alternatively, any num- 
strates respectively occupy different positions relative to the 50 ber of substrates can be recombined painvise in an iterative 
remainder of the vector. Denaturation and reannealing gen- fashion with products of one round of recombination anneal- 
erator heteroduplexes similar to that shown in FIG. 1, except ing with a fresh substrate in each round. 
that the nicks occur within the vector component rather than In a further variation, heteroduplexes can be formed from 
at the interface between plasmid and substrate. Initiation of substrates molecules in vector-free form, and the heterodu- 
amplification outside the substrate component of a vector 55 plexes subsequently cloned into vectors. Such can be 
has the advantage that it is not necessary to design primers achieved by asymmetric amplification of first and second 
specific for the substrate borne by the vector. substrates as shown in FIG. 3. Asymmetric or single primer 
Although FIG. 1 is exemplified for two substrates, the PCR amplifies only one strand of a duplex. By appropriate 
above scheme can be extended to any number of substrates. selection of primers, opposite strands can be amplified from 
For example, an initial population of vector bearing sub- 60 two different substrates. On reannealing amplification 
strates can be divided into two pools. One pool is PCR- products, heteroduplexes are formed from opposite strands 
amplified from one set of primers, and the other pool from of the two substrates. Because only one strand is amplified 
another. The amplification products are denatured and from each substrate, reannealing does not reform homodu- 
annealed as before. Heteroduplexes can form containing one plexes (other than for small quantities of unamplified 
strand from any substrate in the first pool and one strand 65 substrate). The process can be extended to allow recombi- 
from any substrate in the second pool. Alternatively, three or nation of any number of substrates using analogous strate- 
more substrates cloned into multiple copies of a vector can gies to those described with respect to FIG. 1. For example, 
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substrates can be divided into two pools, and each pool general, a suitable vector has an origin of replication rec- 
subject to the same asymmetric amplification, such that ognized in the desired host cell, a selection maker capable of 
amplification products of one pool can only anneal with being expressed in the intended host cells and/or regulatory 
amplification products of the other pool, and not with each sequences to support expression of genes within substrates 
other. Alternatively, shuffling can proceed painvise in an s being shuffled. 
iterative manner, in which recombinants formed from het- V. Types of Host Cells eroduplexes of first and second substrates, are subsequently 
subjected to heteroduplex formation with a third substrate. In general any type of cells supporting DNA repair and 
Point mutations can also be introduced at a desired level replication of heteroduplexes introduced into the cells can be 
during PCR amplification. 10 used. Cells of particular interest are the standard cell types 
FIG. 4 shows another approach of selecting for hetero- CommonlY used in genetic engineering, such as bacteria, 
duplexes relative to ~ o m o ~ u p ~ e x e s ,  First and second sub- particularly, E. coli (16, 17). Suitable E. coli strains include 
strates are:isolated by PCR amplification from separate E. coli mutS, mutL, dam-, and/or recA+, E.coli XL-10-Gold 
vectors. The substrates are denatured and allowed to anneal ([Tet'A(mcrA)183 A(mcrCB-hsdSMR-mrr)173 endA1 
forming both heteroduplexes and reconstructed homodu- 15 suPE44 thi-1 reCAI gYrA96 relA1 lac Hte1 [F 'Prom 
plexes. The products of annealing are digested with restric- camr1)3 E. co1iES1301 mutS 
tion enzymes X and Y. X has a site in the first substrate but [Genotype: lacZ53, mutS201:Tn5, thYm6, rha-5, metB1, 
not the second substrate, and vice versa for Y. Enzyme X deoC, lN(rrnD-rrnE)l (20, 24, 28-42). Preferred E. 
cuts reconstructed homoduplex from the first substrate and strains are E. ITs1, (Str3, thr, leu, 
enzyme Y cuts reconstructed homoduplex from the second 20 end% thi-1, lacy, g a k  g a k  ara tons, tsx, dam, dcm, suPE44, 
substrate. Neither enzyme cuts heteroduplexes. Heterodu- A(lac-Prom), LF3 traD363 ProA+B'1ac14ZAM15]~ which 
plexes can effectively be separated from restriction frag- have  mal cellular mismatch repair systems (17). This 
merits of ~ o m o ~ u p ~ e x e s  by further cleavage with enzymes A strain type repairs mismatches and unmatches in the hetero- 
and B having sites proximate to the ends of both the first and duplex with little Strand-sPecific Preference. Further, 
second substrates, and ligation of the products into vector zs because this strain is dam- and dcm-, plasmid isolated from 
having cohesive ends compatible with ends from the strain is unmethylated and therefore particularly ame- 
digestion with A and B, only heteroduplexes cut with A and nable for further rounds of DNAduplex formationimismatch 
B can ligate with the vector. Alternatively, heteroduplexes repair (see below). Other suitable bacterial cells include 
can be separated from restriction fragments of homodu- gram-negative and gram-positive, such as Bacillus, 
plexes by size selection on gels. The above process can be 30 Pseudomonas~ and Salmonella. 
generalized to N substrates by cleaving the mixture of Eukaryotic organisms are also able to carry out mismatch 
heteroduplexes and homoduplexes with N enzymes, each repair (43-48). Mismatch repair systems in both prokaryotes 
one of which cuts a different substrate and no other sub- and eukaryotes are thought to play an important role in the 
strate. Heteroduplexes can be formed by directional cloning. maintenance of genetic fidelity during DNA replication, 
Two substrates for heteroduplex formation can be obtained 35 Some of the genes that play important roles in mismatch 
by PCR amplification of chromosomal DNA and joined to repair in prokaryotes, particularly mutS and mutL, have 
opposite ends of a linear vector. Directional cloning can be homologs in eukaryotes. in the outcome of genetic 
achieved by digesting the vector with two different enzymes, recombinations, and in genome stability. Wild-type or 
and digesting or adapting first and second substrates to be mutant S. cerevisiae has been shown to carry out mismatch 
respectively compatible with cohesive ends of only of the 40 repair of heteroduplexes (49-56), as have COS-1 monkey 
two enzymes used to cut the vector. The first and second cells (57). Preferred strains of yeast are Picchia and Sac- 
substrates can thus be ligated at opposite ends of a linearized charomyces. Mammalian cells have been shown to have the 
vector fragment. This scheme can be extended to any capacity to repair G-T to G-C base pairs by a short-patch 
number of substrates by using principles analogous to those mechanism (38, 58-63). Mammalian cells (e.& mouse, 
described for FIG. 1. For example, substrates can be divided 45 hamster, primate, human), both cell lines and primary CUI- 
into two pools before ligation to the vector. Alternatively, tures can also be used. Such cells include stem cells, 
recombinant products formed by heteroduplex formation of including embryonic stem cells, zygotes, fibroblasts, 
first and second substrates, can subsequently undergo het- lymphocytes, Chinese hamster ovary (CHO), mouse fibro- 
eroduplex formation with a third substrate. blasts (NIH3T3), kidney, liver, muscle, and skin cells. Other 
SO eucaryotic cells of interest include plant cells, such as maize, 
rice, wheat, cotton, soybean, sugarcane, tobacco, and arabi- IV. Vectors and Transformation 
In general, substrates are incorporated into vectors either dopsis; fish, algae, fungi (aspergillus, podospora, 
before or after the heteroduplex formation step. Avariety of neurospora), insect (e,g, ,  bacula lepidoptera) (see, 
cloning vectors typically used in genetic engineering are Winnacker, ''From Genes to Clones," VCH Publishers, New 
suitable. 
The vectors containing the DNA segments of interest can vivo repair occurs in a wide variety of prokaryotic and 
be transferred into the host cell by standard methods, eukaryotic cells. Use of mammalian cells is advantage in 
depending on the type of cellular host. For example, calcium certain application in which substrates encode polypeptides 
chloride transformation is commonly utilized for prokary- that are expressed only in mammalian cells or which are 
otic cells, whereas calcium Phosphate treatment. 60 intended for use in mammalian cells. However, bacterial and 
LiPofection, Or electroPoration may be used for other 4 -  yeast cells are advantageous for screening large libraries due 
hlar hosts. Other methods used to transform m m m d i a n  to the higher transformation frequencies attainable in these 
cells include the use of Polybrene, protoplast fusion, strains, 
liposomes, electroporation, and microinjection, and 
biolisitics (see, generally, Sambrook et al., supra). Viral 65 V. In Vitro DNA Repair Systems 
vectors can also be packaged in vitro and introduced by As an alternative to introducing annealed products into 
infection. The choice of vector depends on the host cells. In host cells, annealed products can be exposed a DNA repair 
Tnlo (Tet? 
scs 110 
55 York, (1987), which is incorporated herein by reference). 
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system in vitro. The DNA repair system can be obtained as 
extracts from repair-competent E. coli, yeast or any other 
cells (64-67). Repair-competent cells are lysed in appropri- 
ate buffer and supplemented with nucleotides. DNA is 
incubated in this cell extract and transformed into competent 
cells for replication. 
VI. Screening and Selection 
After introduction of annealed products into host cells, the 
host cells are typically cultured to allow repair and replica- 
tion to occur and optionally, for genes encoded by poly- 
nucleotides to be expressed. The recombinant polynucle- 
otides can be subject to further rounds of recombination 
using the heteroduplex procedures described above, or other 
shuffling methods described below. However, whether after 
one cycle of recombination or several, recombinant poly- 
nucleotides are subjected to screening or selection for a 
desired property. In some instances, screening or selection in 
performed in the same host cells that are used for DNA 
repair. In other instances, recombinant polynucleotides, their 
expression products or secondary metabolites produced by 
the expression products are isolated from such cells and 
screened in vitro. In other instances, recombinant polynucle- 
otides are isolated from the host cells in which recombina- 
tion occurs and are screened or selected in other host cells. 
For example, in some methods, it is advantageous to allow 
DNA repair to occur in a bacterial host strain, but to screen 
an expression product of recombinant polynucleotides in 
eucaryotic cells. The recombinant polynucleotides surviving 
screening or selection are sometimes useful products in 
themselves. In other instances, such recombinant polynucle- 
otides are subjected to further recombination with each other 
or other substrates. Such recombination can be effected by 
the heteroduplex methods described above or any other 
shuffling methods. Further round(s) of recombination are 
followed by further rounds of screening or selection on an 
iterative basis. Optionally, the stringency of selection can be 
increased at each round. 
The nature of screening or selection depends on the 
desired property sought to be acquired. Desirable properties 
of enzymes include high catalytic activity, capacity to confer 
resistance to drugs, high stability, the ability to accept a 
wider (or narrower) range of substrates, or the ability to 
function in nonnatural environments such as organic sol- 
vents. Other desirable properties of proteins include capacity 
to bind a selected target, secretion capacity, capacity to 
generate an immune response to a given target, lack of 
immunogenicity and toxicity to pathogenic microorganisms. 
Desirable properties of DNA or RNA polynucleotides 
sequences include capacity to specifically bind a given 
protein target, and capacity to regulate expression of oper- 
ably linked coding sequences. Some of the above properties, 
such as drug resistance, can be selected by plating cells on 
the drug. Other properties, such as the influence of a 
regulatory sequence on expression, can be screened by 
detecting appearance of the expression product of a reporter 
gene linked to the regulatory sequence. Other properties, 
such as capacity of an expressed protein to be secreted, can 
be screened by FACSTM, using a labelled antibody to the 
protein. Other properties, such as immunogenicity or lack 
thereof, can be screened by isolating protein from individual 
cells or pools of cells, and analyzing the protein in vitro or 
in a laboratory animal. 
VII. Variations 
1. Demethylation 
Most cell types methylate DNA in some manner, with the 
pattern of methylation differing between cells types. Sites of 
14 
m e t h y l a t i o n  i n c l u d e  5 - m e t h y l c y t o s i n e  (m5C) ,  
N4-methylcytosine (m4C) and N6-methyladenine (m6A), 
5 - h y d r o  x y m e  t h y I C  y t o  s i n e  a n d  
5-hydroxymethyluracil (hm5U). In E. coli, methylation is 
s effected by Dam and Dcm enzymes. The methylase specified 
by the dam gene methylates the N6-position of the adenine 
residue in the sequence GATC, and the methylase specified 
by the dcm gene methylates the C5-position of the internal 
cytosine residue in the sequence CCWGG. DNAfrom plants 
i o  and mammal is often subject to CG methylation meaning 
that CG or CNG sequences are methylated. Possible effects 
of methylated on cellular repair are discussed by references 
In some methods, DNA substrates for heteroduplex for- 
is mation are at least partially demethylated on one or both 
strands, preferably the latter. Demethylation of substrate 
DNA promotes efficient and random repair of the heterodu- 
plexes. In heteroduplexes formed with one strand dam- 
methylated and one strand unmethylated, repair is biased to 
20 the unmethylated strand, with the methylated strand serving 
as the template for correction. If neither strand is 
methylated, mismatch repair occurrs, but showes insignifi- 
cant strand preference (23, 24). 
Demethylation can be performed in a variety of ways. In 
zs some methods, substrate DNA is demethylated by PCR- 
amplification. In some instances, DNA demethylation is 
accomplished in one of the PCR steps in the heteroduplex 
formation procedures described above. In other methods, an 
additional PCR step is performed to effect demethylation. In 
30 other methods, demethylation is effected by passaging sub- 
strate DNA through methylation deficient host cells (e.g. an 
E. coli dam-dcm- strain). In other methods, substrate DNA 
is demethylated in vitro using a demethylating enzymes. 
Demethylated DNA is used for heteroduplex formation 
35 using the same procedures described above. Heteroduplexes 
are subsequently introduced into DNA-repair-proficient but 
restriction-enzyme-defective cells to prevent degradation of 
the unmethylated heteroduplexes. 
2. Sealing Nicks 
40 Several of the methods for heteroduplex formation 
described above result in circular heteroduplexes bearing 
nicks in each strand. These nicks can be sealed before 
introducing heteroduplexes into host cells. Sealing can be 
effected by treatment with DNA ligase under standard 
45 ligating conditions. Ligation forms a phosphodiester bond to 
link two adjacent bases separated by a nick in one strand of 
double helix of DNA. Sealing of nicks increases the fre- 
quency of recombination after introduction of heterodu- 
plexes into host cells. 
( h m 5  C )  
18-20. 
SO 3. Error Prone PCR Attendant To Amplification 
Several of the formats described above include a PCR 
amplification step. Optionally, such a step can be performed 
under mutagenic conditions to induce additional diversity 
between substrates. 
VIII. Other Shuffling Methods 
The methods of heteroduplex formation described above 
can be used in conjunction with other shuffling methods. For 
example, one can perform one cycle of heteroduplex 
60 shuffling, screening or selection, followed by a cycle of 
shuffling by another method, followed by a further cycle of 
screening or selection. Other shuffling formats are described 
by WO 95122625; U.S. Pat. No. 5,605,793; U.S. Pat. No. 
5,811,238; WO 96119256; Stemmer, Science 270, 1510 
65 (1995); Stemmer et al., Gene, 164, 49-53 (1995); Stemmer, 
BioiTechnology, 13, 549-553 (1995); Stemmer, Proc. Natl. 
Acad. Sci. USA 91, 10747-10751 (1994); Stemmer, Nature 
55 
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370, 389-391 (1994); Crameri et al., Nature Medicine, 
2(1):1-3, (1996); Crameri et al., Nature Biotechnology 14, 
315-319 (1996); WO 98142727; WO 98141622; WO 
98105764 and WO 98142728, WO 98127230 (each of which 
is incorporated by reference in its entirety for all purposes). 
IX. Protein Analogs 
Proteins isolated by the methods also serve as lead 
compounds for the development of derivative compounds. 
The derivative compounds can include chemical modifica- 
tions of amino acids or replace amino acids with chemical 
structures. The analogs should have a stabilized electronic 
configuration and molecular conformation that allows key 
functional groups to be presented in substantially the same 
way as a lead protein. In particular, the non-peptic com- 
pounds have spatial electronic properties which are compa- 
rable to the polypeptide binding region, but will typically be 
much smaller molecules than the polypeptides, frequently 
having a molecular weight below about 2 CHD and prefer- 
ably below about 1 CHD. Identification of such non-peptic 
compounds can be performed through several standard 
methods such as self-consistent field (CSF) analysis, con- 
figuration interaction (CHI) analysis, and normal mode 
dynamics analysis. Computer programs for implementing 
these techniques are readily available. See Rein et al., 
Computer-Assisted Modeling of Receptor-Ligand Interac- 
tiom (Alan Liss, New York, 1989). 
IX. Pharmaceutical Compositions 
Polynucleotides, their expression products, and secondary 
metabolites whose formation is catalyzed by expression 
products, generated by the above methods are optionally 
formulated as pharmaceutical compositions. Such a compo- 
sition comprises one or more active agents, and a pharma- 
ceutically acceptable carrier. A variety of aqueous carriers 
can be used, e.g., water, buffered water, phosphate-buffered 
saline (PBS), 0.4% saline, 0.3% glycine, human albumin 
solution and the like. These solutions are sterile and gener- 
ally free of particulate matter. The compositions may contain 
pharmaceutically acceptable auxiliary substances as 
required to approximate physiological conditions such as pH 
adjusting and buffering agents, toxicity adjusting agents and 
the like, for example, sodium acetate, sodium chloride, 
potassium chloride, calcium chloride and sodium is selected 
primarily based on fluid volumes, viscosities, and so forth, 
in accordance with the particular mode of administration 
selected. 
EXAMPLES 
Example 1 
Novel Rhizobium Flaa Genes from Recombination 
of Rhizobium Lupini Flaa And Rhizobium Meliloti 
FlaA 
Bacterial flagella have a helical filament, a proximal hook 
and a basal body with the flagellar motor (68). This basic 
design has been extensively examined in E. coli and S. 
typhimurium and is broadly applicable to many other bac- 
teria as well as some archaea. The long helical filaments are 
polymers assembled from flagellin subunits, whose molecu- 
lar weights range between 20,000 and 65,000, depending on 
the bacterial species (69). Two types of flagellar filaments, 
named plain and complex, have been distinguished by their 
electron microscopically determined surface structures (70). 
Plain filaments have a smooth surface with faint helical 
16 
lines, whereas complex filaments exhibit a conspicuous 
helical pattern of alternating ridges and grooves. These 
characteristics of complex flagellar filaments are considered 
to be responsible for the brittle and (by implication) rigid 
5 structure that enables them to propel bacteria efficiently in 
viscous media (71-73). Whereas flagella with plain fila- 
ments can alternate between clockwise and counter clock- 
wise rotation (68), all known flagella with complex fila- 
ments rotate only clockwise with intermittent stops (74). 
Since this latter navigation pattern is found throughout 
bacteria and archaea, it has been suggested that complex 
flagella may reflect the common background of an ancient, 
basic motility design (69). 
Differing from plain bacterial flagella in the fine structure 
of their filaments dominated by conspicuous helical bands 
and in their fragility, the filaments are also resistant against 
heat decomposition (72). Schmitt et al. (75) showed that 
bacteriophage 7-7-1 specifically adsorbs to the complex 
flagella of R. lupini H 13-3 and requires motility for a 
productive infection of its host. Though the flagellins from 
20 R. meliloti and R. lupini are quite similar, bacteriophage 
7-7-1 does not infect R.meliloti. Until now complex flagella 
have been observed in only three species of soil bacteria: 
Pseudomonas rhodos (73), R.meliloti (76), and R. lupini 
H13-3 (70, 72). Cells of R.lupini H13-3 posses 5 to 10 
2s peritrichously inserted complex flagella, which were first 
isolated and analyzed by high resolution electron micros- 
copy and by optical diffraction (70). 
Maruyama et al. (77) further found that a higher content 
of hydrophobic amino acid residues in the complex filament 
30 may be one of the main reasons for the unusual properties of 
complex flagella. By measuring mass per unit length and 
obtaining three-dimensional reconstruction from electron 
micrographs, Trachtenberg et al. (73, 78) suggested that the 
complex filaments of R. lupini are composed of functional 
35 dimers. FIG. 6 shows the comparison between the deduced 
amino acid sequence of the R. lupini H13-3 FlaA and the 
deduced amino acid sequence of the R. meliloti FlaA. 
Perfect matches are indicated by vertical lines, and conser- 
vative exchanges are indicated by colons. The overall iden- 
40 tity is 56%. The R.lupini flaA and R.meliloti flaA were 
subjected to in vitro heteroduplex formation followed by in 
vivo repair in order to create novel FlaA molecules and 
structures. 
A. Methods 
pRL20 containing R. lupini H-13-3 flaAgene and pRM40 
containing R.meliloti flaA gene are shown in FIGS. 6A and 
6B. These plasmids were isolated from E. coli SCSllO (free 
from dam- and dcm-type methylation). About 3.0 pg. of 
unmethylated pRL20 and pRM40 DNA were digested with 
SO Bam HI and Eco RI, respectively, at 37" C. for 1 hour. After 
agarose gel separation, the linearized DNA was purified with 
Wizard PCR Prep kit (Promega, Wis., USA). Equimolar 
concentrations (2.5 nM) of the linearized unmethylated 
pRL20 and pRM40 were mixed in lxSSPE buffer (180 mM 
ss NaC1, 1 mM EDTA, 10 mM NaH2P04, pH 7.4). After 
heating at 96" C. for 10 minutes, the reaction mixture was 
immediately cooled at 0" C. for 5 minutes. The mixture was 
incubated at 68" C. for 2 hour for heteroduplexes to form. 
One microliter of the reaction mixture was used to trans- 
60 form 50wf E. coli ES 1301 mutS, E. coli SCSllO and E. coli 
JM109 competent cells. The transformation efficiency with 
E. coli JM109 competent cells was about seven times higher 
than that of E. coli SCSllO and ten times higher than that of 
E. coli ES1301 mutS, although the overall transformation 
65 efficiencies were 10-200 times lower than those of control 
transformations with the close, covalent and circular pUC19 
plasmid. 
10 
45 
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Two clones were selected at random from the E. coli little similarity to other possibly related enzymes such as 
SCSllO transformants and two from E. coli ES1301 mutS penicillin acylase that a structural model reliable enough to 
transformants, and plasmid DNA was isolated from these guide a rational effort to engineer the ECB deacylase will be 
four clones for further DNA sequencing analysis. difficult to build. We therefore decided to use directed 
B. Results 5 evolution (85) to improve this important activity. 
FIG. 7 shows (a) the sequence of SCSOl (clone#l from E. Protocols suitable for mutagenic PCR and random- 
coli SCSllO transformant library), (b) the sequence of Priming recombination of the 2.4 kb ECB deacYlase gene 
SCSO2 (clone #2 from E. coli SCSllO transformant library), (73% G+C) have been described recently (86). Here, we 
(.) the sequence of ESOl (clone #1 from E,  coli ~ ~ 1 3 0 1  further describe the use of heteroduplex recombination to 
transformant library), and (d) the sequence of ES02 (clone i o  generate new ECB deacYlase with enhanced specific activ- 
#2 from E. coli ES1301 transformant library). All four ity. 
sequences were different from wild-type R. lupini fld and In this case, two Actinoplanes utahensis ECB deacylase 
R. meliloti flaA sequences. Clones SCSO2, ESOl and ES02 mutants, M7-2 and M16, which show higher specific activity 
all contain a complete open-reading frame, but SCSOl was at pH 5.5 and in the presence of 10% MeOH were recom- 
truncated. FIG. 8 shows that recombination mainly occurred 1s bined using technique of the in vitro heteroduplex formation 
in the loop regions (unmatched regions). The flaA mutant and in vivo mismatch repair. 
library generated from R. meliloti flaA and R. lupini flaAcan FIG. 12 shows the physical maps of plasmids pM7-2 and 
be transformed into E. coli SCS110, ES1301, XL10-Gold pM16 which contain the genes for the M7-2 and M16 ECB 
and JM109, and transformants screened for functional FlaA deacylase mutants. Mutant M7-2 was obtained through 
recombinants. 20 mutagenic PCR performed directly on whole Streptomyces 
lividans cells containing wild-type ECB deacylase gene, 
expressed from plasmid pSHP150-24 Streptomyces with 
pM7-2 show 1.5 times the specific activity of cells express- 
ing the wild-type ECB deacylase (86). Clone pM16 was 
zs obtained using the random-priming recombination tech- 
nique as described (86, 87). It shows 2.4 times specific 
activity of the wild-type ECB deacylase clone, 
Example 2 
Directed Evolution of ECB Deacylase for Variants 
with Enhanced Specific Activity 
StrePtomYces are among the most important industrial 
microorganisms due to their ability to produce numerous 
important secondary metabolites (including many A, Methods: 
antibiotics) as well as large amounts of enzymes. The D N A ( P M ~ - ~  and p ~ 1 6 )  (FIG, 9) 
approach described here can be used with little modification 3o were purified from E,  coli s c s 2 1 0  (in separate reactions), 
for directed evolution of native Streptomyces enzymes, About 5.0 pg of unmethylated ~ 7 - 2  and ~ 1 6  DNA were 
some or all of the genes in a metabolic pathways, as well as digested with Xho I and Psh AI, respectively, at 37" C. for 
other heterologous enzymes expressed in Streptomyces. 1 hour (FIG. 10). After agarose gel separation, the linearized 
New antifungal agents are critically needed by the large DNA was purified using a Wizard PCR Prep Kit (Promega, 
and growing numbers of immune-compromised AIDS, 3s Wis., USA). Equimolar concentrations (2.0 nM) of the 
organ transplant and cancer chemotherapy patients who linearized unmethylated pM7-2 and pM16 DNAwere mixed 
lipopeptide produced by some species of Aspergillus, has 10 mM NaH,PO,, pH 7.4). After heating at 96" C. for 10 
~ 7 - 2  and ~ 1 6  
suffer opportunistic infections. Echinocandin B (ECB), a in 1xSSpE buffer (1xSSpE: 180 mM NaC1, 1.0 mM EDTA, 
been studied extensively as a potential antifungal. Various minutes, the reaction mixture is immediately cooled at 0" c .  
antifungal agents with significantly reduced toxicity have 40 for 5 minutes. The mixture was incubated at 68" C. for 3 
been generated by replacing the linoleic acid side chain ofA. hours to promote formation of heteroduplexes. 
nidulam echinocandin B with different aryl side chains One microliter of the reaction mixture was used to trans- 
(79-83). The cyclic hexapeptide ECB nucleus precursor for form 50 pl of E.coli ES1301 mutS, SCSllO and JM109 
the chemical acylation is obtained by enzymatic hydrolysis competent cells. All transformants from E. coli ~ ~ 1 3 0 1  
of ECB using Actinoplanes utahensis ECB deacylase. To 4s mutS were pooled and E. coli SCSllO were pooled. A 
maximize the conversion of ECB into intact nucleus, this plasmid pool was isolated from each pooled library, and this 
reaction is carried out at pH 5.5 with a small amount of pool was used to transform s. lividans m3 protoplasts to 
miscible organic solvent to solubilize the ECB substrate. form a mutant library for &acylase activity screening. 
The product cyclic hexapeptide nucleus is unstable at pH Transformants from the S. lividans TK23 libraries were 
above 5.5 during the long incubation required to fully so screened for ECB deacylase activity with an in situ plate 
deacylate ECB (84). The PH optimum of ECB deacylase, assay. Transformed protoplasts were allowed to regenerate 
however, is 8.0-8.5 and its activity is reduced at pH 5.5 and on R2YE agar plates for 24 hr at 30" C. and to develop in 
in the presence of more than 2.5% ethanol (84). To improve the presence of thiostrepton for 48 hours. When the colonies 
production of ECB nucleus it is necessary to increase the grew to the proper size, 6 ml of 0.7% agarose solution 
activity of the ECB deacylase under these process-relevant 5s containing 0.5 mg/ml ECB in 0.1 M sodium acetate buffer 
conditions. (PH 5.5) was poured on top of each R2YE-agar plate and 
Relatively little is known about ECB deacylase. The allowed to develop for 18-24 hr at 30" C. Colonies sur- 
enzyme is a heterodimer whose two subunits are derived by rounded by a clearing zone larger than that of a control 
processing of a single precursor protein (83). The 19.9 kD colony containing wild-type plasmid pSHP150-2*, were 
a-subunit is separated from the 60.4 kD 0-subunit by a 60 selected for further characterization. 
15-amino acid spacer peptide that is removed along with a Selected transformants were inoculated into 20 ml 
signal peptide and another spacer peptide in the native medium containing thiostrepton and grown aerobically at 
organism. The polypeptide is also expressed and processed 30" C. for 48 hours, at which point they were analyzed for 
into functional enzyme in Streptomyces lividans, the organ- ECB deacylase activity using HPLC. 100 pl of whole broth 
ism used for large-scale conversion of ECB by recombinant 65 was used for a reaction at 30" C. for 30 minutes in 0.1 M 
ECB deacylase. The three-dimensional structure of the NaAc buffer (pH 5.5) containing 10% (vi.) MeOH and 200 
enzyme has not been determined, and its sequence shows so pgiml of ECB substrate. The reactions were stopped by 
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adding 2.5 volumes of methanol, and 20 pl of each sample shift of 1.Ck1.5 units in the optimum to lower pH, as 
were analyzed by HPLC on a 1 0 0 ~ 4 . 6  mm polyhydroxy- compared to wild type. 
ethyl aspartamide column (PolyLC Inc., Columbia, Md., The time courses of deactivation of the purified ECB 
USA) at room temperature using a linear acetonitrile gradi- deacylase mutant M15 was measured in 0.1 M NaAc (PH 
ent starting with 50:50 of A B  (A=93% acetonitrile, 0.1% s 5.5) at 30" C. No significant difference in stability was 
phosphoric acid; B=70% acetonitrile, 0.1% phosphoric acid) observed between wild type and mutant M15. 
and ending with 30:70 of A B  in 22 min at a flow rate of 2.2 The DNA mutations with respect to the wild type ECB 
mlimin. The areas of the ECB and ECB nucleus peaks were deacylase sequence and the positions of the amino acid 
calculated and subtracted from the areas of the correspond- substitutions in the evolved variants M7-2, M16 and M15 
ing peaks from a sample culture of S. lividam containing i o  are summarized in FIG. 12. 
pIJ702* in order to estimate the ECB deacylase activity. The heteroduplex recombination technique can recom- 
2.0 ml pre-cultures of positive mutants were used to bine parent sequences to create novel progeny. Recombina- 
inoculate 50-ml medium and allowed to grow at 30" C. for tion of the M7-2 and M16 genes yielded M15, whose 
96 hr. The supernatants were further concentrated to 1/30 activity is higher than any of its parents (Fid. 13). Of the six 
their original volume using an Amicon filtration unit is base substitutions in M15, five (at positions a50, a71, 857, 
(Beverly, Mass., USA) with molecular weight cutoff of 10 8129 and 8340) were inherited from M7-2, and the other one 
kD. The resulting enzyme samples were diluted with an (830) came from M16. 
equal volume of 50 mM KH,P04 (PH 6.0) buffer and were This approach provides an alternative to existing methods 
applied to Hi-Trap ion exchange column (Pharmacia of DNA recombination and is particularly useful in recom- 
Biotech, Piscataway, N.J., USA). The binding buffer was 50 20 bining large genes or entire operons. This method can be 
mM KH,PO, (PH 6.0), and the elution buffer was 50 mM used to create recombinant proteins to improve their prop- 
KH,PO, (pH 6.0) containing 1.0 M NaC1. A linear gradient erties or to study structure-function relationship. 
from 0 to 1.0 M NaCl was applied in 8 column volumes with 
a flow rate of 2.7 mlimin. The ECB deacylase fraction 
eluting at 0.3 M NaCl was concentrated and the buffer was zs 
exchanged for 50 MM KH,PO, (pH 6.0) using Centricon-10 
units. Enzyme purity was verified by SDS-PAGE using 
Coomassie Blue stain, and the concentration was determined This example demonstrates the use in vitro heteroduplex 
using the Bio-Rad Protein Assay Reagent (Hercules, Calif., formation followed by in Vivo repair for combining 
USA). 30 sequence information from two different sequences in order 
A modified HpLC assay was used to determine the to improve the thermostability of Bacillus subtilis subtilisin 
activities of the ECB deacylase mutants on ECB substrate E. 
(84). Four pg of each purified ECB deacylase mutant was Genes RC1 and RC2 encode thermostable B. sublilis 
used for activity assay reaction at 30" C. for 30 minutes in subtilisin E variants (88). The mutations at base positions 
0.1 M NaAc buffer (pH 5.5) containing 10% (viv) MeOH 3s 1107 in RC1 and 995 in RC2 (FIG. 14), giving rise to amino 
and different concentrations of ECB substrate. Assays were acid substitutions Asn218iSer (N218S) and Asnl8liAsp 
performed in duplicate. The reactions were stopped by (N181 ID), lead to improvements in subtilisin E thermosta- 
adding 2.5 volumes of methanol, and the HPLC assays were bility; the remaining mutations, both synonymous and 
carried out as described above. The absorbance values were nonsynonymous, have no detectable effects on thermosta- 
recorded, and the initial rates were calculated by least- 40 bility. At 65" C., the single variants N181D and N218S have 
squares regression of the time progress curves from which approximately 3-fold and 2-fold longer half-lives, 
the Km and the kcat were calculated. respectively, than wild subtilisin E, and variants containing 
Activities as a function of pH were measured for the both mutations have half-lives that are %fold longer (88). 
purified ECB deacylases at 30" C. at different pH values: 5, The different half-lives in a population of subtilisin E 
5.5 and 6 (0.1 M acetate buffer); 7, 7.5, 8 and 8.5 (0.1 M 4s variants can therefore be used to estimate the efficiency by 
phosphate buffer); 9 and 10 (0.1 M carbonate buffer) using which sequence information is combined. In particular, 
the HPLC assay. Stab es of purified ECB deacylases were recombination between these two mutations (in the absence 
were determined at 30" C. in 0.1 M NaAc buffer (PH 5.5) of point mutations affecting thermostability) should generate 
containing 10% methanol. Samples were withdrawn at dif- a library in which 25% of the population exhibits the 
ferent time intervals, and the residual activity was measured SO thermosiability of the double mutant. Similarly, 25% of the 
in the same buffer with the HPLC assay described above. population should exhibit wild-type like stability, as N181D 
B. Results and N218S are eliminated at equal frequency. We used the 
FIG. 11 shows that after one round of applying this fractions of the recombined population as a diagnostic 
heteroduplex repair technique on the mutant M7-2 and M16 A. Methods 
genes, one mutant (M15) from about 500 original transfor- ss The strategy underlying this example is shown in FIG. 15. 
mants was found to possess 3.1 times the specific activity of Subtilisin E thermostable mutant genes RC1 and RC2 
wild-type. Wild type and evolved M15 ECB deacylases (FIG. 14) are 986-bp fragments including 45 nt of subtilisin 
were purified and their kinetic parameters for deacylation of E prosequence, the entire mature sequence and 113 nt after 
ECB were determined by HPLC. The evolved deacylases the stop codon. The genes were cloned between Bam HI and 
M15 has an increased catalytic rate constant, k,,, by 205%. 60 Nde I in E. coli/B. subtilis shuttle vector pBE3, resulting in 
The catalytic efficiency (kc,&) of M20 is enhanced by a pBE3-1 and pBE3-2, respectively. Plasmid DNA pBE3-1 
factor of 2.9 over the wild-type enzyme. and pBE3-2 was isolated from E.coli SCS110. 
Initial rates of deacylation with the wild type and M15 at About 5.0 pg of ummethylated pBE3-1 and pBE3-2 DNA 
different pH values from 5 to 10 were determined at 200 were digested with Bam HI and Nde I, respectively, at 37" 
pgiml of ECB. The recombined M15 is more active than 65 C. for 1 hour. After agarose gel separation, equimolar 
wild type at pH 5-8. Although the pH dependence of the concentrations (2.0 nM) of the linearized unmethylated 
enzyme activity in this assay is not strong, there is a definite pBE3-1 and pBE3-2 were mixed in lxSSPE buffer (180 mM 
Example 3 
Novel Thermostable Bacillus 
Variants 
Subtilisin E 
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NaC1, 1.0 mM EDTA, 10 mM NaH,PO,, pH 7.4). After 
heating at 96" C. for 10 minutes, the reaction mixture was 
immediately cooled at 0" C. for 5 min. The mixture was 
incubated at 68" C. for 2 hr for heteroduplexes to form. 
One microliter of the reaction mixture was used to trans- 
form 50 pl of E. coli ES 1301 mutS, E. coli SCSllO and E. 
coli HBlOl competent cells. 
The transformation efficiency with E. coli HBlOl com- 
petent cells was about ten times higher than that of E. coli 
SCSllO and 15 times higher than that of E. coli ES1301 
mutS. But in all these cases, the transformation efficiencies 
were l e 2 5 0  times lower than that of the transformation 
with closed, covalent and circular control pUC19 plasmids. 
Five clones from E. coli SCSllO mutant library and five 
from E. coli ES1301 mutS library were randomly chosen, 
and plasmid DNA was isolated using a QIAprep spin 
plasmid miniprep kit for further DNA sequencing analysis. 
About 2,000 random clones from E. coli HBlOl mutant 
library were pooled and total plasmid DNA was isolated 
using a QIAGEN-100 column. 0.5-4.0 pg of the isolated 
plasmid was used to transform Bacillus subtilis DB428 as 
described previously (88). 
About 400 transformants from the Bacillus subtilis 
DB428 library were subjected to screening. Screening was 
performed using the assay described previously (88), on 
succinyl-Ala-Ala-Pro-Phe-p-nitroanilide. B. subtilis DB428 
containing the plasmid library were grown on LB plates 
containing kanamycin (20 pg/ml) plates. After 18 hours at 
37" C. single colonies were picked into 96-well plates 
containing 200 pl SGikanamycin medium per well. These 
plates were incubated with shaking at 37" C. for 24 hours to 
let the cells to grow to saturation. The cells were spun down, 
and the supernatants were sampled for the thermostability 
assay. 
Two replicates of 96-well assay plates were prepared for 
each growth plate by transferring 10 pl of supernatant into 
the replica plates. The subtilisin activities were then mea- 
sured by adding 100 pl of activity assay solution (0.2 mM 
succinyl-Ala-Ala-Pro-Phe-p-nitroanilide, 100 mM Tris- 
HC1, 10 mM CaCl,, pH 8.0, 37" C.). Reaction velocities 
were measured at 405 nm to over 1.0 min in a ThermoMax 
microplate reader (Molecular Devices, Sunnyvale Calif.). 
Activity measured at room temperature was used to calcu- 
late the fraction of active clones (clones with activity less 
than 10% of that of wild type were scored as inactive). Initial 
activity (Ai) was measured after incubating one assay plate 
at 65" C. for 10 minutes by immediately adding 100 pl of 
prewarmed (37" C.) assay solution (0.2 mM succinyl-Ala- 
Ala-Pro-Phe-p-nitroanilide, 100 mM Tris-HC1, pH 8.0, 10 
mM CaCl,, pH 8.0) into each well. Residual activity (Ar) 
was measured after 40 minute incubation. 
B. Results 
In vitro heteroduplex formation and in vivo repair was 
carried out as described above. Five clones from E. coli 
SCSllO mutant library and five from E. coli ES1301 mutS 
libraries were selected at random and sequenced. FIG. 14 
shows that four out of the ten clones were different from the 
parent genes. The frequency of occurrence of a particular 
point mutation from parent RC1 or RC2 in the resulting 
genes ranged from 0% to 50%, and the ten point mutations 
in the heteroduplex have been repaired without strong 
strand-specific preference. 
Since none of the ten mutations locates within the dcm 
site, the mismatch repair appears generally done via the E. 
coli long-patch mismatch repair systems. The system repairs 
different mismatches in a strand-specific manner using the 
state of N6-methylation of adenine in GATC sequences as 
22 
the major mechanism for determining the strand to be 
repaired. With heteroduplexes methylated at GATC 
sequences on only one DNA strand, repair was shown to be 
highly biased to the unmethylated strand, with the methy- 
s lated strand serving as the template for correction. If neither 
strand was methylated, mismatch repair occurred, but 
showed little strand preference (23,24). These results shows 
that it is preferable to demethylate the DNA to be recom- 
bined to promote efficient and random repair of the hetero- 
The rates of subtilisin E thermo-inactivation at 65" C. 
were estimated by analyzing the 400 random clones from the 
Bacillus subtilis DB428 library. The thermostabilities 
obtained from one 96-well plate are shown in FIG. 16, 
is plotted in descending order. About 12.9% of the clones 
exhibited thermostability comparable to the mutant with the 
N181D and N218S double mutations. Since this rate is only 
half of that expected for random recombination of these two 
markers, it indicates that the two mismatches at positions 
20 995 and 1107 within the heteroduplexes have been repaired 
with lower position randomness. 
Sequence analysis of the clone exhibiting the highest 
thermostability among the screened 400 transformants from 
the E. coli SCSllO heteroduplex library confirmed the 
zs presence of both N181D and N218S mutations. Among the 
400 transformants from the B.sublilis DB428 library that 
were screened, approximately 91% of the clones expressed 
N18ID- and/or N218S-type enzyme stabilities, while about 
8.0% of the transformants showed only wild-type subtilisin 
Less than 1.0% inactive clone was found, indicating that 
few new point mutations were introduced in the recombi- 
nation process. This is consistent with the fact that no new 
point mutations were identified in the ten sequenced genes 
3s (FIG. 14). While point mutations may provide useful diver- 
sity for some in vitro evolution applications, they can also be 
problematic for recombination of beneficial mutations, espe- 
cially when the mutation rate is high. 
i o  duplexes. 
30 E stability. 
40 Example 4 
Optimizing Conditions for the Heteroduplex 
Recombination. 
We have found that the efficiency of heteroduplex recom- 
4s bination can differ considerably from gene to gene [17,57]. 
In this example, we investigate and optimize a variety of 
parameters that improve recombination efficiency. DNA 
substrates used in this example were site-directed mutants of 
green fluorescent protein from Aequorea victoria. The GFP 
S O  mutants had a stop codon(s) introduced at different locations 
along the sequence that abolished their fluorescence. Fluo- 
rescent wild type protein could be only restored by recom- 
bination between two or more mutations. Fraction of fluo- 
rescent colonies was used as a measure of recombination 
A. Methods 
About 2-4 pg of each parent plasmid was used in one 
recombination experiment. One parent plasmid was digested 
with Pst I endonuclease another parent with EcoRI. Linear- 
60 ized plasmids were mixed together and 20xSSPE buffer was 
added to the final concentration lx(180 mM NaC1, 1 mM 
EDTA, 10 mM NaH,PO,, pH 7.4). The reaction mixture was 
heated at 96" C. for 4 minutes, immediately transferred on 
ice for 4 minutes and the incubation was continued for 2 
Target genes were amplified in a PCR reaction with 
primers corresponding to the vector sequence of pGFP 
ss efficiency. 
65 hours at 68" C. 
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plasmid. Forward primer: 5 '-CCGACTGGAAAGC 
GGGCAGTG-3', reverse primer 5'-CGGGGCTGGCTT 
AACTATGCGG-3'. PCR products were mixed together and 
purified using Qiagen PCR purification kit. Purified products 
were mixed with 20xSSPE buffer and hybridized as 
described above. Annealed products were precipitated with 
ethanol or purified on Qiagen columns and digested with 
EcoRI and PstI enzymes. Digested products were ligated 
into PstI and EcoRI digested pGFP vector. 
dUTP was added into PCR reaction at final concentrations 
200 pM, 40 pM, 8 pM, 1.6 pM, 0.32 pM. PCR reaction and 
subsequent cloning procedures were performed as described 
above. 
Recombinant plasmids were transformed into XLlO E. 
coli strain by a modified chemical transformation method. 
Cells were plated on ampicillin containing LB agar plates 
and grown overnight at 37" C., followed by incubation at 
room temperature or at 4" C. until fluorescence developed. 
B. Results. 
1. Effect of Ligation on Recombination Efficiency. 
Two experiments have been performed to test the effect of 
breaks in the DNA heteroduplex on the efficiency of recom- 
bination. In one experiment heteroduplex plasmid was 
treated with DNA ligase to close all existing single-strand 
breaks and was transformed in identical conditions as an 
unligated sample (see Table 1). The ligated samples show up 
to 7-fold improvement in recombination efficiency over 
unligated samples. 
In another experiment, dUTP was added into PCR reac- 
tion to introduce additional breaks into DNAupon repair by 
uracyl N-glycosylase in the host cells. Table 2 shows that 
d U M P  i n c o r p o r a t i o n  s igni f icant ly  s u p p r e s s e d  
recombination, the extent of suppression increasing with 
increased dUTP concentration. 
2. Effect of Plasmid Size on the Efficiency of Heterodu- 
plex Formation. 
Plasmid size was a significant factor affecting recombi- 
nation efficiency. Two plasmids pGFP (3.3 kb) and a Bacil- 
lus shuttle vector pCTl (about 9 kb) were used in preparing 
circular heteroduplex-like plasmids following traditional 
heteroduplex protocol. For the purpose of this experiment 
(to study the effect of plasmid size on duplex formation), 
both parents had the same sequences. While pGFP formed 
about 30-40% of circular plasmid, the shuttle vector yielded 
less than 10% of this form. 
Increase in plasmid size decreases concentration of the 
ends in the vicinity of each and makes annealing of very 
long (>0.8 kb) ends that are single-stranded more difficult. 
This difficulty is avoided by the procedure shown in FIG. 3, 
in which heteroduplex formation occurs between substrates 
in vector-free form, and, heteroduplexes are subsequently 
inserted into a vector. 
3. Efficiency of Recombination vs. Distance Between 
Mutations 
A series of GFP variants was recombined pairwise to 
study the effect of distance between mutations on the effi- 
ciency of recombination. Parental genes were amplified by 
PCR, annealed and ligated back into pGFP vector. Hetero- 
duplexes were transformed into XLlO E. coli strain. 
The first three columns in Table 3 show the results of three 
independent experiments and demonstrate the dependence 
of recombination efficiency on the distance between muta- 
tions. As expected recombination becomes less and less 
efficient for very close mutations. 
However, it is still remarkable that long-patch repair has 
been able to recombine mutations separated by only 27 bp. 
24 
The last line in Table 3 represents recombination between 
one single and one double mutants. Wild type GFP could 
only be restored in the event of double crossover with each 
individual crossover occurring in the distance of 99 bp only, 
s demonstrating the ability of this method to recombine 
multiple, closely-spaced mutations. 
4. Elimination of the Parental Double Strands From 
Heteroduplex Preparations. 
Annealing of substrates in vector-free form offers size- 
i o  advantages relative to annealing of substrates as components 
of vectors, but does not allow selection for heteroduplexes 
relative to homoduplexes simply by transformation into 
host. Asymmetric PCR reactions with only one primer for 
each parent seeded with appropriate amount of previously 
is amplified and purified gene fragment were run for 100 
cycles, ensuring a 100-fold excess of one strand over 
another. Products of these asymmetrical reactions were 
mixed and annealed together producing only a minor 
amount of nonrecombinant duplexes. The last column in 
20 Table 3 shows the recombination efficiency obtained from 
these enriched heteroduplexes. Comparison of the first three 
columns with the fourth one demonstrates the improvement 
achieved by asymmetric synthesis of the parental strands. 
While the foregoing invention has been described in some 
zs detail for purposes of clarity and understanding, it will be 
clear to one skilled in the art from a reading of this disclosure 
that various changes in form and detail can be made without 
departing from the true scope of the invention. All publica- 
tions and patent documents cited in this application are 
30 incorporated by reference in their entirety for all purposes to 
the same extent as if each individual publication or patent 
document were so individually denoted. 
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SEQUENCE L I S T I N G  
<160>  NUMBER OF SEQ I D  NOS: 1 1  
<210>  SEQ I D  NO 1 
<211>  LENGTH: 4 1 0  
<212>  TYPE: PRT 
<213>  ORGANISM: R h i z o b i u m  l u p i n i  
<2 2 0 > FEATURE : 
<223>  OTHER INFORMATION: f l a g e l l i n  A ( F l a A )  
<400>  SEQUENCE: 1 
M e t  A l a  S e r  V a l  L e u  T h r  A s n  I l e  A s n  A l a  M e t  S e r  A l a  L e u  G l n  T h r  
1 5 1 0  1 5  
L e u  A r g  S e r  I l e  S e r  S e r  A s n  M e t  G l u  A s p  T h r  G l n  S e r  A r g  I l e  S e r  
2 0  2 5  3 0  
S e r  G l y  M e t  A r g  V a l  G l y  S e r  A l a  S e r  A s p  A s n  A l a  A l a  T y r  T r p  S e r  
35  40 45 
I le  A l a  T h r  T h r  M e t  A r g  S e r  A s p  A s n  A l a  S e r  L e u  S e r  A l a  V a l  G l n  
5 0  5 5  6 0  
A s p  A l a  I l e  G l y  L e u  G l y  A l a  A l a  L y s  V a l  A s p  T h r  A l a  S e r  A l a  G l y  
65  7 0  7 5  8 0  
M e t  A s p  A l a  V a l  I l e  A s p  V a l  V a l  L y s  G l n  I l e  L y s  A s n  L y s  L e u  V a l  
8 5  9 0  95  
T h r  A l a  G l n  G l u  S e r  S e r  A l a  A s p  L y s  T h r  L y s  I l e  G l n  G l y  G l u  V a l  
1 0 0  1 0 5  1 1 0  
L y s  G l n  L e u  G l n  G l u  G l n  L e u  L y s  G l y  I l e  V a l  A s p  S e r  A l a  S e r  Phe 
1 1 5  1 2 0  1 2 5  
S e r  G l y  G l u  A s n  T r p  L e u  L y s  G l y  A s p  L e u  S e r  T h r  T h r  T h r  T h r  L y s  
1 3 0  1 3 5  1 4 0  
S e r  V a l  V a l  G l y  S e r  Phe V a l  A r g  G l u  G l y  G l y  T h r  V a l  S e r  V a l  L y s  
1 4 5  1 5 0  1 5 5  1 6 0  
T h r  I l e  A s p  T y r  A l a  L e u  A s n  A l a  S e r  L y s  V a l  L e u  V a l  A s p  T h r  A r g  
1 6 5  1 7 0  1 7 5  
A l a  T h r  G l y  T h r  L y s  T h r  G l y  I l e  L e u  A s p  T h r  A l a  T y r  T h r  G l y  L e u  
1 8 0  1 8 5  1 9 0  
A s n  A l a  A s n  T h r  V a l  T h r  V a l  A s p  I l e  A s n  L y s  G l y  G l y  V a l  I l e  T h r  
1 9 5  2 0 0  2 0 5  
G l n  A l a  S e r  V a l  A r g  A l a  T y r  S e r  T h r  A s p  G l u  M e t  L e u  S e r  L e u  G l y  
2 1 0  2 1 5  2 2 0  
A l a  L y s  V a l  A s p  G l y  A l a  A s n  S e r  A s n  V a l  A l a  V a l  G l y  G l y  G l y  S e r  
2 2 5  2 3 0  2 3 5  2 4 0  
A l a  S e r  S e r  A r g  S e r  T h r  A l a  A l a  G l y  L e u  A r g  V a l  A l a  S e r  T h r  L e u  
2 4 5  2 5 0  2 5 5  
A r g  P r o  P r o  S e r  P r o  H i s  G l n  H i s  G l n  S e r  L e u  A l a  S e r  L e u  P r o  P r o  
US 6,537,746 B2 
32 
- con t inued  
2 6 0  2 6 5  2 7 0  
L e u  T h r  P r o  P r o  L e u  L y s  L e u  V a l  L e u  G l n  L e u  L e u  P r o  V a l  T h r  P r o  
2 7 5  2 8 0  2 8 5  
S e r  S e r  S e r  T h r  L y s  P r o  T h r  A l a  A l a  P r o  V a l  G l n  V a l  A s n  L e u  T h r  
2 9 0  2 9 5  3 0 0  
G l n  S e r  V a l  L e u  T h r  M e t  A s p  V a l  S e r  S e r  M e t  S e r  S e r  T h r  A s p  V a l  
3 0 5  3 1 0  3 1 5  3 2 0  
G l y  S e r  T y r  L e u  T h r  G l y  V a l  G l u  L y s  A l a  L e u  T h r  S e r  L e u  T h r  S e r  
3 2 5  3 3 0  3 3 5  
A l a  G l y  A l a  G l u  L e u  G l y  S e r  I l e  L y s  G l n  A r g  I l e  A s p  L e u  G l n  V a l  
3 4 0  3 4 5  3 5 0  
A s p  Phe A l a  S e r  L y s  L e u  G l y  A s p  A l a  L e u  A l a  L y s  G l y  I l e  G l y  A r g  
3 5 5  3 6 0  3 6 5  
L e u  V a l  A s p  A l a  A s p  M e t  A s n  G l u  G l u  S e r  T h r  L y s  L e u  L y s  A l a  L e u  
3 7 0  3 7 5  3 8 0  
G l n  T h r  G l n  G l n  G l n  L e u  A l a  I l e  G l n  S e r  L e u  S e r  I l e  A l a  A s n  S e r  
3 8 5  3 9 0  3 9 5  400  
A s p  S e r  G l n  A s n  I l e  L e u  S e r  L e u  Phe A r g  
4 0 5  410  
<210>  SEQ I D  NO 2 
<211>  LENGTH: 3 9 4  
<212>  TYPE: PRT 
<213>  ORGANISM: R h i z o b i u m  m e l i l o t i  
<220> FEATURE: 
<223>  OTHER INFORMATION: f l a g e l l i n  A ( F l a A )  
<400>  SEQUENCE: 2 
M e t  T h r  S e r  I l e  L e u  T h r  A s n  A s n  S e r  A l a  M e t  A l a  A l a  L e u  S e r  T h r  
1 5 1 0  1 5  
L e u  A r g  S e r  I l e  S e r  S e r  S e r  M e t  G l u  A s p  T h r  G l n  S e r  A r g  I l e  S e r  
20  2 5  3 0  
S e r  G l y  L e u  A r g  V a l  G l y  S e r  A l a  S e r  A s p  A s n  A l a  A l a  T y r  T r p  S e r  
3 5  4 0  4 5  
I l e  A l a  T h r  T h r  M e t  A r g  S e r  A s p  A s n  G l n  A l a  L e u  S e r  A l a  V a l  G l n  
5 0  5 5  60  
A s p  A l a  L e u  G l y  L e u  G l y  A l a  A l a  L y s  V a l  A s p  T h r  A l a  T y r  S e r  G l y  
65  7 0  75  8 0  
M e t  G l u  S e r  A l a  I l e  G l u  V a l  V a l  L y s  G l u  I l e  L y s  A l a  L y s  L e u  V a l  
85  9 0  9 5  
A l a  A l a  T h r  G l u  A s p  G l y  V a l  A s p  L y s  A l a  L y s  I l e  G l n  G l u  G l u  I l e  
1 0 0  1 0 5  1 1 0  
T h r  G l n  L e u  L y s  A s p  G l n  L e u  T h r  S e r  I l e  A l a  G l u  A l a  A l a  S e r  Phe 
1 1 5  1 2 0  1 2 5  
S e r  G l y  G l u  A s n  T r p  L e u  G l n  A l a  A s p  L e u  S e r  G l y  G l y  P r o  V a l  T h r  
1 3 0  1 3 5  1 4 0  
L y s  S e r  V a l  V a l  G l y  G l y  Phe V a l  A r g  A s p  S e r  S e r  G l y  A l a  V a l  S e r  
1 4 5  1 5 0  1 5 5  1 6 0  
V a l  L y s  L y s  V a l  A s p  T y r  S e r  L e u  A s n  T h r  A s p  T h r  V a l  L e u  Phe A s p  
1 6 5  1 7 0  1 7 5  
T h r  T h r  G l y  A s n  T h r  G l y  I l e  L e u  A s p  L y s  V a l  T y r  A s n  V a l  S e r  G l n  
1 8 0  1 8 5  1 9 0  
A l a  S e r  V a l  T h r  L e u  P r o  V a l  A s n  V a l  A s n  G l y  T h r  T h r  S e r  G l u  T y r  
1 9 5  2 0 0  2 0 5  
T h r  V a l  G l y  A l a  T y r  A s n  V a l  A s p  A s p  L e u  I l e  A s p  A l a  S e r  A l a  T h r  
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34 
- con t inued  
2 1 0  2 15 2 2 0  
Phe Asp Gly Asp Tyr Ala Asn Val Gly Ala Gly Ala Leu Ala Gly Asp 
225 230 235 2 4 0  
Tyr Val Lys Val Gln Gly S e r  Trp Val Lys Ala Val Asp Val Ala Ala 
245 250 255 
Thr Gly Gln Glu Val Val Tyr Asp Asp Gly Thr Thr Lys Trp Gly Val 
2 6 0  265 2 7 0  
Asp Thr Thr Val Thr Gly Ala Pro  Ala Thr Asn Val Ala Ala Pro  Ala 
275 280 285 
S e r  I l e  Ala Thr I l e  Asp I l e  Thr I l e  Ala Ala Gln Ala Gly Asn Leu 
2 9 0  295 300 
Asp Ala Leu I l e  Ala Gly Val Asp Glu Ala Leu Thr Asp M e t  Thr S e r  
305 310 3 15 320 
Ala Ala Ala S e r  Leu Gly S e r  I l e  S e r  S e r  Arg I l e  Asp Leu Gln S e r  
325 330 335 
Asp Phe Val Asn Lys Leu S e r  Asp S e r  I l e  Asp S e r  Gly Val Gly Arg 
340 345 350 
Leu Val Asp Ala Asp M e t  Asn Glu Glu S e r  Thr Arg Leu Lys Ala Leu 
355 360 365 
Gln Thr Gln Gln Gln Leu Ala I l e  Gln Ala Leu S e r  I l e  Ala Asn S e r  
370 375 380 
Asp S e r  Gln Asn Val Leu S e r  Leu Phe Arq 
385 
<210> 
<211> 
<212> 
<213> 
<220> 
<223> 
< 4 0 0 >  
390 
SEQ I D  NO 3 
LENGTH: 1 2 0 1  
TYPE: DNA 
ORGANISM: A r t i f i c i a l  Sequence 
FEATURE : 
OTHER INFORMATION: D e s c r i p t i o n  of A r t i f i c i a l  Sequence:SCSOl mosaic 
flaA gene c r e a t e d  by i n  v i t r o  he te roduplex  
format ion  fo l lowed by i n  v i v o  r e p a i r  
SEQUENCE: 3 
atggcaagcg t t c t c a c a a a  c a t t a a c g c a  a t g t c t g c t c  t t c a g a c g c t  g c g t t c g a t t  
t c t t c c a a c a  tggaagacac ccagagccgt  a t t t c c a g c g  gca tgcgcgt  t g g t t c g g c t  
tccgacaacg  c c g c t t a t t g  g t c t a t c g c g  accacca tgc  gc tcggacaa  t g c c t c g c t t  
t c c g c t g t t c  a g g a t g c a a t  t g g c c t c g g t  gccgccaagg t c g a t a c c g c  t t c g g c g g g t  
a tgga tgcgg t t a t c g a t g t  t g t a a a g c a g  a tcaagaaca  a a c t g g t c a c  tgccaccgaa  
gacggcgtcg acaaggccaa ga tccaagaa  g a a a t c a c t c  agc tcaagga  ccagctgacg  
agca tcgccg  a c g c g g c t t c  c t t c t c c g g t  gaaaactggc tcaagggcga t c t t t c c a c g  
acgacaacca a a t c a g t g g t  t g g c t c c t t c  g t t c g t g a a g  gcggtaccgt  a t c g g t c a a g  
a c c a t c g a t t  a c g c t c t g a a  t g c t t c c a a g  g t t c t g g t g g  a tacccgcgc  aacgggcacc 
aagaccggca t t c t g g a c a a  g g t c t a c a a c  g tc tcgcagg caagcgtcac  gc tgacggtc  
aacaccaacg g c g t c g a a t c  ccaggcc tcc  g t c c g c g c c t  a t t c g c t g g a  g t c c c t c a c c  
gaagccggtg c g g a g t t c c a  g g g c a a c t a t  g c t c t t c a g g  gcggtaacag c t a c g t c a a g  
g tcgaaaacg  t c t g g g t t c g  agctgagacc gca tcaacac  c a g t c g c t g g  c a a g t t t g c c  
g c c g c t t a c a  ccgccgctga a g c t g g t a c t  gcagctgc tg  ccggtgacgc c a t c a t c g t c  
gacgaaacca acagcggcgc cggtgcaggt  a a a c c t c a c c  c a g t c g g t c c  t g a c c a t g g a  
t g t c a g c t c g  a t g a g c t c g a  cggatg tcgg  c a g c t a c c t c  acgggcgtgg a a a a g g c t c t  
6 0  
1 2 0  
180 
2 4 0  
300 
360 
4 2 0  
480 
540 
6 0 0  
6 6 0  
7 2 0  
780 
840 
9 0 0  
9 6 0  
US 6,537,746 B2 
36 
- con t inued  
caccagcc tg  acgagcgctg g c g c t g a a c t  c g g c t c t a t c  aaacagcgca t c g a t c t g c a  1 0 2 0  
g g t t g a t t t t  g c t t c c a a g c  tgggcgacgc t c t c g c a a a a  g g t a t t g g c c  g t c t c g t t g a  1 0 8 0  
t g c t g a c a t g  a a t g a a g a g t  c c a c t a a g c t  t a a g g c t c t t  cagacgcagc agcagctggc 1 1 4 0  
t a t c c a g t c g  c t c t c c a t c g  caaacagcga c tcgcagaac  a t t c t g t c g c  t g t t c c g t t a  1 2 0 0  
a 1 2 0 1  
<210>  SEQ I D  NO 4 
<211>  LENGTH: 1 2 2 9  
<212>  TYPE: DNA 
<213>  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
<223>  OTHER INFORMATION: D e s c r i p t i o n  of A r t i f i c i a l  Sequence:SCS02 mosaic 
flaA gene c r e a t e d  by i n  v i t r o  he te roduplex  
format ion  fo l lowed by i n  v i v o  r e p a i r  
<400>  SEQUENCE: 4 
atgacgagca t t c t c a c c a a  caac tccgca  atggccgcgc t t t c c g g a g t  g c g c t c g a t c  
t c t t c c a g c a  tggaagacac gcagagccgc a t c t c c t c c g  g c c t t c g c g t  cggt tcggcc  
tccgacaacg  c c g c c t a c t g  g t c g a t t g c g  accacca tgc  gc tccgacaa  c c a g g c c c t t  
t c g g c c g t c c  aggacgccct  cggcctcggc gccgccaagg t t g a t a c c g c  c t a t t c c g g t  
a tggaa tcgg  c g a t c g a a g t  c g t t a a g g a a  a tcaagaaca  a a c t g g t c a c  t g c t c a g g a a  
t c t t c t g c c g  acaaaacgaa ga t tcagggc  gaagtcaagc a g c t t c a g g a  gcagt tgaag  
g g c a t c g t t g  a t t c c g c t t c  c t t c t c c g g t  gagaactggc tgcaggcgga cc tcagcggc  
ggcgccgtca ccaagagcgt  cg tcggctcg  t t c g t c c g t g  acggaagcgg t t c c g t a g c c  
gtcaagaagg t c g a t t a c g c  t c t g a a t g c t  t c c a a g g t t c  t g g t g g a t a c  ccgcgcaacg 
ggcaccaaga c c g g c a t t c t  c g a t a c t g c t  t a t a c c g g c c  t t a a c g c g a a  cacggtgacg 
g t t g a t a t c a  acaagggcgg c g t g a t c a c c  caggcc tccg  t c c g c g c c t a  t t c c a c g g a c  
g a a a t g c t c t  ccctcggcgc a a a g g t c g a t  ggcgcaaaca g c a a c g t t g c  t g t t g g c g g c  
g g c t c c g c t t  c g t c a a g g t c  gacggcagct  gggt taaggg t a g c g t c g a c  gc tgcggcc t  
cca tcaccgc  a tcaaccggc  gccaccggtc  aagaaa tcgc  cgccaccacg acggcagctg 
g t a c c a t c a c  tgcagacagc t g g g t c g t c g  a t g t c g g c a a  c g c t c c t g c c  g c c a a c g t t t  
cggccggcca g tcggtcgcg  a a c a t c a a c a  t c g t c g g a a t  gggctcgacg ga tg tcggca  
g c t a c c t c a c  gggcgtggaa a a g g c t c t c a  ccagca tgac  cagcgctgcc  g c c t c g c t c g  
g c t c c a t c t c  c t c g c g c a t c  gacctgcaga g c g a a t t c g t  caacaagctc  t c g g a c t c g a  
tcgagtcggg cg tcggccgt  c t c g t c g a c g  cggacatgaa cgaggagtcg acccgcc tca  
aggccctgca gacccagcag cagc tcgcca  t c c a g g c c c t  g t c g a t c g c c  a a c t c g g a c t  
cgcagaacgt  c c t g t c g c t c  t t c c g c t a a  
6 0  
1 2 0  
1 8 0  
2 4 0  
3 0 0  
3 6 0  
4 2 0  
4 8 0  
5 4 0  
6 0 0  
6 6 0  
7 2 0  
7 8 0  
8 4 0  
9 0 0  
9 6 0  
0 2 0  
0 8 0  
1 1 4 0  
1 2 0 0  
1 2 2 9  
<210>  SEQ I D  NO 5 
<211>  LENGTH: 1 2 2 8  
<212>  TYPE: DNA 
<213>  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
<223>  OTHER INFORMATION: D e s c r i p t i o n  of A r t i f i c i a l  Sequence:ESOl mosaic 
flaA gene c r e a t e d  by i n  v i t r o  he te roduplex  
format ion  fo l lowed by i n  v i v o  r e p a i r  
<400>  SEQUENCE: 5 
atgacgagca t t c t c a c c a a  caac tccgca  atggccgcgc t t t c c g g a g t  g c g c t c g a t c  6 0  
t c t t c c a g c a  tggaagacac gcagagccgc a t c t c c t c c g  g c c t t c g c g t  cggt tcggcc  1 2 0  
US 6,537,746 B2 
37 38 
- con t inued  
tccgacaacg  c c g c c t a c t g  g t c g a t t g c g  accacca tgc  gc tccgacaa  c c a g g c c c t t  
t c g g c c g t c c  aggacgccct  cggcctcggc gccgccaagg t t g a t a c c g c  c t a t t c c g g t  
a tggaa tcgg  c g a t c g a a g t  c g t t a a g g a a  a tcaaggcca  a g c t c g t a g c  tgccaccgaa  
gacggcgtcg acaaggccaa ga tccaagaa  g a a a t c a c t c  agc tcaagga  ccagctgacg  
agca tcgccg  a c g c g g c t t c  c t t c t c c g g t  gagaactggc tgcaggcgga cc tcagcggc  
ggcgccgtca ccaagagcgt  cg tcggctcg  t t c g t c c g t g  acggaagcgg t t c c g t a g c c  
g tcaagacca  t c g a t t a c g c  t c t g a a t g c t  t c c a a g g t t c  t g g t g g a t a c  ccgcgacacg 
g tcggcgata  c c g g c a t t c t  ggacaaggtc  t a c a a c g t c t  cgcaggcaag c g t c a c g c t g  
acggtcaaca  ccaacggcgt  cgaa tcgcag  c a t a c g g t t g  c t g c c t a t t c  gc tggagtcc  
c tcaccgaag  ccggtgcgga g t tccagggc  a a c t a t g c t c  t tcagggcgg t a a c a g c t a c  
g tcaaggtcg  acggcagctg g g t t a a g g g t  agcgtcgacg c t g c g g c c t c  ca tcaccgca  
tcaacaccag  t c g c t g g c a a  g t t t g c c g c c  g c t t a c a c c g  ccgc tgaagc  t g g t a c t g c a  
gc tgc tgccg  g t g a c g c c a t  c a t c g t c g a c  gaaaccaaca gcggcgccgg t g c a g g t a a a  
cc tcacccag  t c g g t c c t g a  c c a t g g a t g t  c a g c t c g a t g  agctcgacgg a t g t c g g c a g  
c t a c c t c a c g  ggcgtggaaa a g g c t c t c a c  cagcc tgacg  agcgctggcg c t g a a c t c g g  
c t c c a t c t c c  t c g c g c a t c g  acc tgcagag  c g a a t t c g t c  a a c a a g c t c t  c g g a c t c g a t  
cgagtcgggc g tcggccgtc  t c g t c g a c g c  ggacatgaac gaggagtcga cccgcc tcaa  
ggccctgcag acccagcagc a g c t c g c c a t  ccaggccc tg  t c g a t c g c c a  a c t c g g a c t c  
gcagaacgtc  c t g t c g c t c t  t c c g c t a a  
1 8 0  
2 4 0  
3 0 0  
3 6 0  
4 2 0  
4 8 0  
5 4 0  
6 0 0  
6 6 0  
7 2 0  
7 8 0  
8 4 0  
9 0 0  
9 6 0  
1 0 2 0  
1 0 8 0  
1 1 4 0  
1 2 0 0  
1 2 2 8  
<210>  SEQ I D  NO 6 
<211>  LENGTH: 1 2 0 9  
<212>  TYPE: DNA 
<213>  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
<223>  OTHER INFORMATION: D e s c r i u t i o n  of A r t i f i c i a l  Seauence:ESOZ mosaic 
flaA gene c r e a t e d  by i n  v i t r o  he te roduplex  
format ion  fo l lowed by i n  v i v o  r e p a i r  
<400>  SEQUENCE: 6 
atgacgagca t t c t c a c c a a  caac tccgca  atggccgcgc t t t c c g g a g t  g c g c t c g a t c  
t c t t c c a g c a  tggaagacac gcagagccgc a t c t c c t c c g  g c c t t c g c g t  cggt tcggcc  
tccgacaacg  c c g c c t a c t g  g t c g a t t g c g  accacca tgc  gc tccgacaa  c c a g g c c c t t  
t c g g c c g t c c  aggacgccct  cggcctcggc gccgccaagg t t g a t a c c g c  c t a t t c c g g t  
a tggaa tcgg  c g a t c g a a g t  c g t t a a g g a a  a tcaaggcca  a g c t c g t a g c  tgccaccgaa  
gacggcgtcg acaaggccaa ga tccaagaa  g a a a t c a c t c  agc tcaagga  ccagctgacg  
agca tcgccg  a c g c g g c t t c  c t t c t c c g g t  gagaactggc tgcaggcgga cc tcagcggc  
ggcgccgtca ccaagagcgt  cg tcggctcg  t t c g t c c g t g  acggaagcgg t t c c g t a g c c  
g tcaagacca  t c g a t t a c g c  t c t g a a t g c t  t c c a a g g t t c  t g g t g g a t a c  ccgcgcaacg 
ggcaccaaga c c g g c a t t c t  c g a t a c t g c t  t a t a c c g g c c  t t a a c g c g a a  cacggtgacg 
g t t g a t a t c a  acaagggcgg c g t g a t c a c c  caggcc tccg  t c c g c g c c t a  t t c c a c g g a c  
g a a a t g c t c t  ccc tcaccga  agccggtgcg gagt tccagg  g c a a c t a t g c  t c t t c a g g g c  
g g t a a c a g c t  a c g t c a a g g t  cgaaaacgtc  t g g g t t c g a g  c tgagaccgc  tgcaaccggc  
gccaccggtc  aagaaa tcgc  cgccaccacg acggcagctg g t a c c a t c a c  tgcagacagc  
6 0  
1 2 0  
1 8 0  
2 4 0  
3 0 0  
3 6 0  
4 2 0  
4 8 0  
5 4 0  
6 0 0  
6 6 0  
7 2 0  
7 8 0  
8 4 0  
US 6,537,746 B2 
40 
- con t inued  
t g g g t c g t c g  a t g t c g g c a a  c g c t c c t g c c  g c c a a c g t t t  cggccggcca g tcggtcgcg  9 0 0  
a a c a t c a a c a  t c g t c g g a a t  gggtgcagct  gcgc tcga tg  c c c t g a t c a g  cggtg tcgac  9 6 0  
g c c g c t t t g a  cagaca tgac  cagcgctgcc g c c t c g c t c g  g c t c c a t c t c  c t c g c g c a t c  1 0 2 0  
gacctgcaga g c g a a t t c g t  caacaagctc  t c g g a c t c g a  tcgagtcggg cg tcggccgt  1 0 8 0  
c t c g t c g a c g  cggacatgaa cgaggagtcg acccgcc tca  aggccc tgca  gacccagcag 1 1 4 0  
cagctcgcca  t c c a g g c c c t  g t c g a t c g c c  a a c t c g g a c t  cgcagaacgt  c c t g t c g c t c  1 2 0 0  
t t c c g c t a a  1 2 0 9  
<210>  
<211>  
<212>  
<213>  
<220> 
<223>  
<221>  
<222> 
<400>  
SEQ I D  NO 7 
LENGTH: 4 0 3 9  
TYPE: DNA 
ORGANISM: A r t i f i c i a l  Sequence 
FEATURE : 
OTHER INFORMATION: D e s c r i p t i o n  of A r t i f i c i a l  Sequence:Act inoplanes 
u t a h e n s i s  echinocandin  B ( E C B )  d e a c y l a s e  gene 
mutant  M-15 c r e a t e d  by i n  v i t r o  he te roduplex  
format ion  fo l lowed by i n  v i v o  r e p a i r  
NAME/KEY: CDS 
LOCATION: ( 1 1 9 6 ) . . ( 3 5 5 9 )  
SEQUENCE: 7 
c tgcagcgtg  c c c a g c t g t t  c g t g g t g g t g  atcgcggccg 
gccgccgccg ggccgatcga g t t c g t c g c c  t t c g t c g t g c  
tgcggcggca gccggccgcc c c t g c t c g c c  tcggcgatgc  
ggcgccgacc t g g t c g c t c a  g a t c g t g g t g  gcgccgaagg 
accgcgatga tcggcacccc  g t a c c t g c t c  t g g c t c c t g c  
agcggatgaa cgcccgcc tg  cgtggcgagg g c c t g c a c c t  
tga tcgacgg c c t c g a c g t c  gacgtgcacg acgggctggt  
acgggtgcgg caagtcgacg  c t g c t c a a g g  cgctcggccg 
ggcaggtgc t  gctggacggc cgccgca tcg  accggacccc 
t g c t c g g c g t  gctgccgcag tcgcccaccg  cgcccgaagg 
tga tgcgcgg ccggcacccg caccagacc t  gg t tccggca  
accaggtcgc cgacgcgctg cgctggaccg a c a t g c t g g c  
a c g c c c t c t c  cggcggtcag cgccagcgcg c c t g g a t c a g  
c c g a c c t g c t  gc tgc tggac  gagccgacca c c t t c c t c g a  
t g c t g g a c c t  ggtccgccgg c tgcacgccg  agatgggccg 
acgacc tgag  cctggccgcc cggtacgccg a c c g g c t g a t  
tcg tggcgag  cggggcgccg gacgaggtgc tcaccccggc  
ggctgcgcgc g a t g g t g g t g  cccgacccgg cgaccggcac 
cgcgccccgc c a c c t c g g t g  cgggcctgaa a t c g a t g a g c  
ccgagcgatg a g a g t a t g t g  ggcggtagag c g a g t c t c g a  
acg t c c  t c g  t a c  a t g  cgc c t g  aaa  gca gca gcg 
Thr S e r  S e r  Tyr M e t  Arg Leu Lys Ala Ala Ala 
5 1 0  
a t c  g t g  gcg acc  gca gcc g t g  ccg t c a  ccc  g c t  
I l e  Val Ala Thr Ala Ala Val Pro  S e r  Pro  Ala 
2 0  2 5  
cgctggccgc cg tcgcggtc  
cgcagatcgc  c c t g c g g c t c  
tcggcgcgct  g c t g g t g g t c  
agc tgccggt  c g g c c t g c t c  
t t c g g c g a t c  aagaaaggtg 
cgcgtacggg gacc tgaccg  
c a c c a c c a t c  a tcgggccca  
gc tgc tgcgc  ccgaccggcg 
cacccgtgac  gtggcccggg 
g c t c a c c g t c  gccgacctgg 
g tggtcgcgc  gacgacgagg 
gtacgcggac cgcccggtgg 
c a t g g c g c t g  gcccagggca 
cc tggcccac  caga tcgacg  
gaccgtggtg  a t g g t g c t g c  
cgcgatgaag gacggccgga 
gc tgc tggag  t c g g t c t t c g  
c c c g c t g g t g  a t c c c c c t g c  
g t g g t t g c t t  c a t c g g c c t g  
99999agatg ccgcc 9 t 9  
Va 1 
1 
a t c  gcc t t c  g g t  g t g  
I l e  Ala Phe Gly Val 
1 5  
t c c  ggc agg gaa c a t  
S e r  Gly Arg Glu H i s  
3 0  
6 0  
1 2 0  
1 8 0  
2 4 0  
3 0 0  
3 6 0  
4 2 0  
4 8 0  
5 4 0  
6 0 0  
6 6 0  
7 2 0  
7 8 0  
8 4 0  
9 0 0  
9 6 0  
1 0 2 0  
1 0 8 0  
1 1 4 0  
1 1 9 8  
1 2 4 6  
1 2 9 4  
US 6,537,746 B2 
42 
- con t inued  
gac ggc ggc t a t  gcg gcc c t g  a t c  cgc cgg gcc t c g  t a c  ggc g t c  ccg 
Asp Gly Gly Tyr Ala Ala Leu I l e  Arg Arg Ala S e r  Tyr Gly Val Pro  
3 5  40 45 
cac  a t c  acc  gcc gac gac t t c  ggg agc c t c  g g t  t t c  ggc g t c  ggg t a c  
H i s  I l e  Thr Ala Asp Asp Phe Gly S e r  Leu Gly Phe Gly Val Gly Tyr 
5 0  5 5  6 0  65  
g t g  cag gcc gag gac aac  a t c  t g c  g t c  a t c  gcc gag agc g t a  g t g  acg 
Val Gln Ala Glu Asp Asn I l e  Cys Val I l e  Ala Glu S e r  Val Val Thr 
7 0  75  8 0  
gcc aac  g g t  gag cgg t c g  cgg t g g  t t c  g g t  gcg acc  ggg ccg gac gac 
Ala Asn Gly Glu Arg S e r  Arg Trp Phe Gly Ala Thr Gly Pro  Asp Asp 
85  9 0  9 5  
gcc g a t  g t g  cgc agc gac c t c  t t c  cac  cgc aag gcg a t c  gac gac cgc 
Ala Asp Val Arg S e r  Asp Leu Phe H i s  Arg Lys Ala I l e  Asp Asp Arg 
1 0 0  1 0 5  1 1 0  
g t c  gcc gag cgg c t c  c t c  gaa ggg ccc  cgc gac ggc g t g  cgg gcg ccg 
Val Ala Glu Arg Leu Leu Glu Gly Pro  Arg Asp Gly Val Arg Ala Pro  
1 1 5  1 2 0  1 2 5  
t c g  gac gac g t c  cgg gac cag a t g  cgc ggc t t c  g t c  gcc ggc t a c  aac  
S e r  Asp Asp Val Arg Asp Gln M e t  Arg Gly Phe Val Ala Gly Tyr Asn 
1 3 0  1 3 5  1 4 0  1 4 5  
cac  t t c  c t a  cgc cgc acc  ggc g t g  cac  cgc c t g  acc  gac ccg gcg t g c  
H i s  Phe Leu Arg Arg Thr Gly Val H i s  Arg Leu Thr Asp Pro  Ala Cys 
1 5 0  1 5 5  1 6 0  
cgc ggc aag gcc t g g  g t g  cgc ccg c t c  t c c  gag a t c  g a t  c t c  t g g  c g t  
Arg Gly Lys Ala Trp Val Arg Pro  Leu S e r  Glu I l e  Asp Leu Trp Arg 
1 6 5  1 7 0  1 7 5  
acg t c g  t g g  gac agc a t g  g t c  cgg gcc g g t  t c c  ggg gcg c t g  c t c  gac 
Thr S e r  Trp Asp S e r  M e t  Val Arg Ala Gly Ser  Gly Ala Leu Leu Asp 
1 8 0  1 8 5  1 9 0  
ggc a t c  g t c  gcc gcg acg cca  c c t  aca  gcc gcc ggg ccc  gcg t c a  gcc 
Gly I l e  Val Ala Ala Thr Pro  Pro  Thr Ala Ala Gly Pro  Ala S e r  Ala 
1 9 5  2 0 0  2 0 5  
ccg gag gca ccc  gac gcc gcc gcg a t c  gcc gcc gcc c t c  gac ggg acg 
Pro  Glu Ala Pro  Asp Ala Ala Ala I l e  Ala Ala Ala Leu Asp Gly Thr 
2 1 0  2 1 5  2 2 0  2 2 5  
agc gcg ggc a t c  ggc agc aac  gcg t a c  ggc c t c  ggc gcg cag gcc acc  
S e r  Ala Gly I l e  Gly S e r  Asn Ala Tyr Gly Leu Gly Ala Gln Ala Thr 
2 3 0  2 3 5  2 4 0  
g t g  aac  ggc agc ggg a t g  g t g  c t g  gcc aac  ccg cac  t t c  ccg t g g  cag 
Val Asn Gly S e r  Gly M e t  Val Leu Ala Asn Pro H i s  Phe Pro  Trp Gln 
2 4 5  2 5 0  2 5 5  
ggc gcc gca cgc t t c  t a c  cgg a t g  cac  c t c  aag g t g  ccc  ggc cgc t a c  
Gly Ala Ala Arg Phe Tyr Arg M e t  H i s  Leu Lys Val Pro  Gly Arg Tyr 
2 6 0  2 6 5  2 7 0  
gac g t c  gag ggc gcg gcg c t g  a t c  ggc gac ccg a t c  a t c  ggg a t c  ggg 
Asp Val Glu Gly Ala Ala Leu I l e  Gly Asp Pro I l e  I l e  Gly I l e  Gly 
2 7 5  2 8 0  2 8 5  
cac  aac  cgc acg g t c  gcc t g g  agc cac  acc  g t c  t c c  acc  gcc cgc cgg 
H i s  Asn Arg Thr Val Ala Trp S e r  H i s  Thr Val S e r  Thr Ala Arg Arg 
2 9 0  2 9 5  3 0 0  3 0 5  
t t c  g t g  t g g  cac  cgc c t g  agc c t c  g t g  ccc  ggc gac ccc  acc  t c c  t a t  
Phe Val Trp H i s  Arg Leu S e r  Leu Val Pro  Gly Asp Pro  Thr S e r  Tyr 
3 1 0  3 1 5  3 2 0  
t a c  g t c  gac ggc cgg ccc  gag cgg a t g  cgc gcc cgc acg g t c  acg g t c  
Tyr Val Asp Gly Arg Pro  Glu Arg M e t  Arg Ala Arg Thr Val Thr Val 
3 2 5  3 3 0  3 3 5  
cag acc  ggc agc ggc ccg g t c  agc cgc acc  t t c  cac  gac acc  cgc t a c  
Gln Thr Gly S e r  Gly Pro  Val S e r  Arg Thr Phe H i s  Asp Thr Arg Tyr 
3 4 0  3 4 5  3 5 0  
1 3 4 2  
1 3 9 0  
1 4 3 8  
1 4 8 6  
1 5 3 4  
1 5 8 2  
1 6 3 0  
1 6 7 8  
1 7 2 6  
1 7 7 4  
1 8 2 2  
1 8 7 0  
1 9 1 8  
1 9 6 6  
2 0 1 4  
2 0 6 2  
2 1 1 0  
2 1 5 8  
2 2 0 6  
2 2 5 4  
US 6,537,746 B2 
44 
- con t inued  
ggc ccg g t g  gcc g t g  a t g  ccg ggc acc  t t c  gac t g g  acg ccg gcc acc  
Gly Pro  Val Ala Val M e t  P ro  Gly Thr Phe Asp Trp Thr Pro  Ala Thr 
3 5 5  3 6 0  3 6 5  
gcg t a c  gcc a t c  acc  gac g t c  aac  gcg ggc aac aac  cgc gcc t t c  gac 
Ala Tyr Ala I l e  Thr Asp Val Asn Ala Gly Asn Asn Arg Ala Phe Asp 
3 7 0  3 7 5  3 8 0  3 8 5  
ggg t g g  c t g  cgg a t g  ggc cag gcc aag gac g t c  cgg gcg c t c  aag gcg 
Gly Trp Leu Arg M e t  Gly Gln Ala Lys Asp Val Arg Ala Leu Lys Ala 
3 9 0  3 9 5  4 0 0  
g t c  c t c  gac cgg cac  cag t t c  c t g  ccc  t g g  g t c  aac  g t g  a t c  gcc gcc 
Val Leu Asp Arg H i s  Gln Phe Leu Pro  Trp Val Asn Val I l e  Ala Ala 
405  4 1 0  4 1 5  
gac gcg cgg ggc gag gcc c t c  t a c  ggc g a t  c a t  t c g  g t c  g t c  ccc  cgg 
Asp Ala Arg Gly Glu Ala Leu Tyr Gly Asp H i s  S e r  Val Val Pro  Arg 
4 2 0  4 2 5  4 3 0  
g t g  acc  ggc gcg c t c  g c t  gcc gcc t g c  a t c  ccg gcg ccg t t c  cag ccg 
Val Thr Gly Ala Leu Ala Ala Ala Cys I l e  Pro Ala Pro  Phe Gln Pro  
4 3 5  4 4 0  4 4 5  
c t c  t a c  gcc t c c  agc ggc cag gcg g t c  c t g  gac g g t  t c c  cgg t c g  gac 
Leu Tyr Ala S e r  S e r  Gly Gln Ala Val Leu Asp Gly S e r  Arg S e r  Asp 
4 5 0  4 5 5  4 6 0  465  
t g c  gcg c t c  ggc gcc gac ccc  gac gcc gcg g t c  ccg ggc a t t  c t c  ggc 
Cys Ala Leu Gly Ala Asp Pro  Asp Ala Ala Val Pro  Gly I l e  Leu Gly 
4 7 0  475  4 8 0  
ccg gcg agc c t g  ccg g t g  cgg t t c  cgc gac gac t a c  g t c  acc  aac  t c c  
Pro  Ala S e r  Leu Pro  Val Arg Phe Arg Asp Asp Tyr Val Thr Asn S e r  
485  4 9 0  4 9 5  
aac  gac a g t  cac  t g g  c t g  gcc agc ccg gcc gcc ccg c t g  gaa ggc t t c  
Asn Asp S e r  H i s  Trp Leu Ala S e r  Pro  Ala Ala Pro  Leu Glu Gly Phe 
5 0 0  5 0 5  5 1 0  
ccg cgg a t c  c t c  ggc aac  gaa cgc acc  ccg cgc agc c t g  cgc acc  cgg 
Pro  Arg I l e  Leu Gly Asn Glu Arg Thr Pro  Arg S e r  Leu Arg Thr Arg 
5 1 5  5 2 0  5 2 5  
c t c  ggg c t g  gac cag a t c  cag cag cgc c t c  gcc ggc acg gac g g t  c t g  
Leu Gly Leu Asp Gln I l e  Gln Gln Arg Leu Ala Gly Thr Asp Gly Leu 
5 3 0  5 3 5  5 4 0  5 4 5  
ccc  ggc aag ggc t t c  acc  acc  gcc cgg c t c  t g g  cag g t c  a t g  t t c  ggc 
Pro  Gly Lys Gly Phe Thr Thr Ala Arg Leu Trp Gln Val M e t  Phe Gly 
5 5 0  5 5 5  5 6 0  
aac  cgg a t g  cac  ggc gcc gaa c t c  gcc cgc gac gac c t g  g t c  gcg c t c  
Asn Arg M e t  H i s  Gly Ala Glu Leu Ala Arg Asp Asp Leu Val Ala Leu 
5 6 5  5 7 0  5 7 5  
t g c  cgc cgc cag ccg acc  gcg acc  gcc t c g  aac ggc gcg a t c  g t c  gac 
Cys Arg Arg Gln Pro  Thr Ala Thr Ala S e r  Asn Gly Ala I l e  Val Asp 
5 8 0  5 8 5  5 9 0  
c t c  acc  gcg gcc t g c  acg gcg c t g  t c c  cgc t t c  g a t  gag c g t  gcc gac 
Leu Thr Ala Ala Cys Thr Ala Leu S e r  Arg Phe Asp Glu Arg Ala Asp 
5 9 5  6 0 0  6 0 5  
c t g  gac agc cgg ggc gcg cac  c t g  t t c  acc  gag t t c  gcc c t c  gcg ggc 
Leu Asp S e r  Arg Gly Ala H i s  Leu Phe Thr Glu Phe Ala Leu Ala Gly 
6 1 0  6 1 5  6 2 0  625  
gga a t c  agg t t c  gcc gac acc  t t c  gag g t g  acc g a t  ccg g t a  cgc acc  
Gly I l e  Arg Phe Ala Asp Thr Phe Glu Val Thr Asp Pro  Val Arg Thr 
6 3 0  635  6 4 0  
ccg cgc c g t  c t g  aac  acc  acg g a t  ccg cgg g t a  cgg acg gcg c t c  gcc 
Pro  Arg Arg Leu Asn Thr Thr Asp Pro  Arg Val Arg Thr Ala Leu Ala 
645  6 5 0  6 5 5  
gac gcc g t g  caa  cgg c t c  gcc ggc a t c  ccc  c t c  gac gcg aag c t g  gga 
Asp Ala Val Gln Arg Leu Ala Gly I l e  Pro  Leu Asp Ala Lys Leu Gly 
2 3 0 2  
2 3 5 0  
2 3 9 8  
2 4 4 6  
2 4 9 4  
2 5 4 2  
2 5 9 0  
2 6 3 8  
2 6 8 6  
2 7 3 4  
2 7 8 2  
2 8 3 0  
2 8 7 8  
2 9 2 6  
2 9 7 4  
3 0 2 2  
3 0 7 0  
3 1 1 8  
3 1 6 6  
3 2 1 4  
US 6,537,746 B2 
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- con t inued  
6 6 0  6 6 5  6 7 0  
gac a t c  cac  acc  gac agc cgc ggc gaa cgg cgc a t c  ccc  a t c  cac  g g t  
Asp I l e  H i s  Thr Asp S e r  Arg Gly Glu Arg Arg I l e  Pro  I l e  H i s  Gly 
6 7 5  6 8 0  6 8 5  
ggc cgc ggg gaa gca ggc acc  t t c  aac  g t g  a t c  acc  aac  ccg c t c  g t g  
Gly Arg Gly Glu Ala Gly Thr Phe Asn Val I l e  Thr Asn Pro  Leu Val 
6 9 0  6 9 5  7 0 0  7 0 5  
ccg ggc g t g  gga t a c  ccg cag g t c  g t c  cac  gga aca  t c g  t t c  g t g  a t g  
Pro  Gly Val Gly Tyr Pro  Gln Val Val H i s  Gly Thr S e r  Phe Val M e t  
7 1 0  7 1 5  7 2 0  
gcc g t c  gaa c t c  ggc ccg cac  ggc ccg t c g  gga cgg cag a t c  c t c  acc  
Ala Val Glu Leu Gly Pro  H i s  Gly Pro  S e r  Gly Arg Gln I l e  Leu Thr 
7 2 5  7 3 0  7 3 5  
t a t  gcg cag t c g  acg aac  ccg aac  t c a  ccc  t g g  t a c  gcc gac cag acc  
Tyr Ala Gln S e r  Thr Asn Pro  Asn S e r  Pro  Trp Tyr Ala Asp Gln Thr 
7 4 0  7 4 5  7 5 0  
g t g  c t c  t a c  t c g  cgg aag ggc t g g  gac acc  a t c  aag t a c  acc  gag gcg 
Val Leu Tyr S e r  Arg Lys Gly Trp Asp Thr I le  Lys Tyr Thr Glu Ala 
7 5 5  7 6 0  7 6 5  
cag a t c  gcg gcc gac ccg aac  c t g  cgc g t c  t a c  cgg g t g  gca cag cgg 
Gln I l e  Ala Ala Asp Pro  Asn Leu Arg Val Tyr Arg Val Ala Gln Arg 
7 7 0  7 7 5  7 8 0  7 8 5  
gga cgc t g a c c c a c g t  cacgccggct  cggcccgtgc gggggcgcag ggcgccgatc  
Gly Arg 
g t c t c t g c a t  cgccggtcag ccggggcctg cgtcgaccgg cggcggccgg tcgacgcccg  
cgtcccggcg cagcgactgg ctgaagcgcc aggcgtcggc ggcccggggc a g g t t g t t g a  
a c a t c a c g t a  cgccgggccg ccgtcgagga tgccggcgag g tg tgccagc  t c g g c a t c c g  
t g t a c a c a t g  ccgggcgccg g t g a t g c c g t  gcagccggta  a t a g g c c a t c  ggcgtcagac 
tgcggcgcag gaacgggtcg gcggcgtggg t c a g g t c c a g  c t c c t g g c a c  aagccc tcga  
c c a c c t c g t c  cggccacggg ccgcgcggct  cccacaacag ccggacaccg gccggccggc 
gcgctcgggc gcagaac tca  cgcagtcgcg cgatggcggg t t c g g t c g g c  cggaaac tcg  
ccgggcactg cag 
3 2 6 2  
3 3 1 0  
3 3 5 8  
3 4 0 6  
3 4 5 4  
3 5 0 2  
3 5 5 0  
3 6 0 6  
3 6 6 6  
3 7 2 6  
3 7 8 6  
3 8 4 6  
3 9 0 6  
3 9 6 6  
4 0 2 6  
4 0 3 9  
<210>  SEQ I D  NO 8 
<211>  LENGTH: 7 8 7  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
<223>  OTHER INFORMATION: D e s c r i p t i o n  of A r t i f i c i a l  Sequence:Act inoplanes 
u t a h e n s i s  echinocandin  B ( E C B )  d e a c y l a s e  p r o t e i n  mutant  M-15 
t r a n s c r i b e d  from gene c r e a t e d  by i n  v i t r o  he te roduplex  format ion  
fol lowed by i n  v ivo  r e p a i r  
<400>  SEQUENCE: 8 
Val Thr S e r  S e r  Tyr M e t  Arg Leu Lys Ala Ala Ala I l e  Ala Phe Gly 
1 5 1 0  1 5  
Val I l e  Val Ala Thr Ala Ala Val Pro  S e r  Pro Ala S e r  Gly Arg Glu 
20  2 5  3 0  
H i s  Asp Gly Gly Tyr Ala Ala Leu I l e  Arg Arg Ala S e r  Tyr Gly Val 
3 5  4 0  4 5  
Pro  H i s  I l e  Thr Ala Asp Asp Phe Gly S e r  Leu Gly Phe Gly Val Gly 
5 0  5 5  60  
Tyr Val Gln Ala Glu Asp Asn I l e  Cys Val I l e  Ala Glu S e r  Val Val 
65  7 0  75  8 0  
Thr Ala Asn Gly Glu Arg S e r  Arg Trp Phe Gly Ala Thr Gly Pro  Asp 
85  9 0  9 5  
US 6,537,746 B2 
48 
- con t inued  
A s p  A l a  A s p  V a l  A r g  S e r  A s p  L e u  Phe H i s  A r g  L y s  A l a  I l e  A s p  A s p  
1 0 0  1 0 5  1 1 0  
A r g  V a l  A l a  G l u  A r g  L e u  L e u  G l u  G l y  P r o  A r g  A s p  G l y  V a l  A r g  A l a  
1 1 5  1 2 0  1 2 5  
P r o  S e r  A s p  A s p  V a l  A r g  A s p  G l n  M e t  A r g  G l y  Phe V a l  A l a  G l y  T y r  
1 3 0  1 3 5  1 4 0  
A s n  H i s  Phe L e u  A r g  A r g  T h r  G l y  V a l  H i s  A r g  L e u  T h r  A s p  P r o  A l a  
1 4 5  1 5 0  1 5 5  1 6 0  
C y s  A r g  G l y  L y s  A l a  T r p  V a l  A r g  P r o  L e u  S e r  G l u  I l e  A s p  L e u  T r p  
1 6 5  1 7 0  1 7 5  
A r g  T h r  S e r  T r p  A s p  S e r  M e t  V a l  A r g  A l a  G l y  S e r  G l y  A l a  L e u  L e u  
1 8 0  1 8 5  1 9 0  
A s p  G l y  I l e  V a l  A l a  A l a  T h r  P r o  P r o  T h r  A l a  A l a  G l y  P r o  A l a  S e r  
1 9 5  2 0 0  2 0 5  
A l a  P r o  G l u  A l a  P r o  A s p  A l a  A l a  A l a  I l e  A l a  A l a  A l a  L e u  A s p  G l y  
2 1 0  2 1 5  2 2 0  
T h r  S e r  A l a  G l y  I l e  G l y  S e r  A s n  A l a  T y r  G l y  L e u  G l y  A l a  G l n  A l a  
2 2 5  2 3 0  2 3 5  2 4 0  
T h r  V a l  A s n  G l y  S e r  G l y  M e t  V a l  L e u  A l a  A s n  P r o  H i s  Phe P r o  T r p  
2 4 5  2 5 0  2 5 5  
G l n  G l y  A l a  A l a  A r g  Phe T y r  A r g  M e t  H i s  L e u  L y s  V a l  P r o  G l y  A r g  
2 6 0  2 6 5  2 7 0  
T y r  A s p  V a l  G l u  G l y  A l a  A l a  L e u  I l e  G l y  A s p  P r o  I l e  I l e  G l y  I l e  
2 7 5  2 8 0  2 8 5  
G l y  H i s  A s n  A r g  T h r  V a l  A l a  T r p  S e r  H i s  T h r  V a l  S e r  T h r  A l a  A r g  
2 9 0  2 9 5  3 0 0  
A r g  Phe V a l  T r p  H i s  A r g  L e u  S e r  L e u  V a l  P ro  G l y  A s p  P r o  T h r  S e r  
3 0 5  3 1 0  3 1 5  3 2 0  
T y r  T y r  V a l  A s p  G l y  A r g  P r o  G l u  A r g  M e t  A r g  A l a  A r g  T h r  V a l  T h r  
3 2 5  3 3 0  3 3 5  
V a l  G l n  T h r  G l y  S e r  G l y  P r o  V a l  S e r  A r g  T h r  Phe H i s  A s p  T h r  A r g  
3 4 0  3 4 5  3 5 0  
T y r  G l y  P r o  V a l  A l a  V a l  M e t  P r o  G l y  T h r  Phe A s p  T r p  T h r  P r o  A l a  
3 5 5  3 6 0  3 6 5  
T h r  A l a  T y r  A l a  I l e  T h r  A s p  V a l  A s n  A l a  G l y  A s n  A s n  A r g  A l a  Phe 
3 7 0  3 7 5  3 8 0  
A s p  G l y  T r p  L e u  A r g  M e t  G l y  G l n  A l a  L y s  A s p  V a l  A r g  A l a  L e u  L y s  
3 8 5  3 9 0  3 9 5  400  
A l a  V a l  L e u  A s p  A r g  H i s  G l n  Phe L e u  P r o  T r p  V a l  A s n  V a l  I l e  A l a  
4 0 5  410  4 1 5  
A l a  A s p  A l a  A r g  G l y  G l u  A l a  L e u  T y r  G l y  A s p  H i s  S e r  V a l  V a l  P r o  
420  4 2 5  4 3 0  
A r g  V a l  T h r  G l y  A l a  L e u  A l a  A l a  A l a  C y s  I l e  P r o  A l a  P r o  Phe G l n  
4 3 5  4 4 0  4 4 5  
P r o  L e u  T y r  A l a  S e r  S e r  G l y  G l n  A l a  V a l  L e u  A s p  G l y  S e r  A r g  S e r  
4 5 0  4 5 5  4 6 0  
A s p  C y s  A l a  L e u  G l y  A l a  A s p  P r o  A s p  A l a  A l a  V a l  P r o  G l y  I l e  L e u  
4 6 5  4 7 0  4 7 5  480  
G l y  P r o  A l a  S e r  L e u  P r o  V a l  A r g  Phe A r g  A s p  A s p  T y r  V a l  T h r  A s n  
4 8 5  490  4 9 5  
S e r  A s n  A s p  S e r  H i s  T r p  L e u  A l a  S e r  P r o  A l a  A l a  P r o  L e u  G l u  G l y  
5 0 0  5 0 5  5 1 0  
US 6,537,746 B2 
50 
- con t inued  
Phe P r o  A r g  I l e  L e u  G l y  A s n  G l u  A r g  T h r  P ro  A r g  S e r  L e u  A r g  T h r  
5 1 5  5 2 0  5 2 5  
A r g  L e u  G l y  L e u  A s p  G l n  I l e  G l n  G l n  A r g  L e u  A l a  G l y  T h r  A s p  G l y  
5 3 0  5 3 5  5 4 0  
L e u  P r o  G l y  L y s  G l y  Phe T h r  T h r  A l a  A r g  L e u  T r p  G l n  V a l  M e t  Phe 
5 4 5  5 5 0  5 5 5  5 6 0  
G l y  A s n  A r g  M e t  H i s  G l y  A l a  G l u  L e u  A l a  A r g  A s p  A s p  L e u  V a l  A l a  
5 6 5  5 7 0  5 7 5  
L e u  C y s  A r g  A r g  G l n  P r o  T h r  A l a  T h r  A l a  S e r  A s n  G l y  A l a  I l e  V a l  
5 8 0  5 8 5  5 9 0  
A s p  L e u  T h r  A l a  A l a  C y s  T h r  A l a  L e u  S e r  A r g  Phe A s p  G l u  A r g  A l a  
5 9 5  6 0 0  6 0 5  
A s p  L e u  A s p  S e r  A r g  G l y  A l a  H i s  L e u  Phe T h r  G l u  Phe A l a  L e u  A l a  
6 1 0  6 1 5  6 2 0  
G l y  G l y  I l e  A r g  Phe A l a  A s p  T h r  Phe G l u  V a l  T h r  A s p  P r o  V a l  A r g  
6 2 5  6 3 0  6 3 5  6 4 0  
T h r  P r o  A r g  A r g  L e u  A s n  T h r  T h r  A s p  P r o  A r g  V a l  A r g  T h r  A l a  L e u  
6 4 5  6 5 0  6 5 5  
A l a  A s p  A l a  V a l  G l n  A r g  L e u  A l a  G l y  I l e  P ro  L e u  A s p  A l a  L y s  L e u  
6 6 0  6 6 5  6 7 0  
G l y  A s p  I l e  H i s  T h r  A s p  S e r  A r g  G l y  G l u  A r g  A r g  I l e  P r o  I l e  H i s  
6 7 5  6 8 0  6 8 5  
G l y  G l y  A r g  G l y  G l u  A l a  G l y  T h r  Phe A s n  V a l  I l e  T h r  A s n  P r o  L e u  
6 9 0  6 9 5  7 0 0  
V a l  P r o  G l y  V a l  G l y  T y r  P r o  G l n  V a l  V a l  H i s  G l y  T h r  S e r  Phe V a l  
7 0 5  7 1 0  7 1 5  7 2 0  
M e t  A l a  V a l  G l u  L e u  G l y  P r o  H i s  G l y  P r o  S e r  G l y  A r g  G l n  I l e  L e u  
7 2 5  7 3 0  7 3 5  
T h r  T y r  A l a  G l n  S e r  T h r  A s n  P r o  A s n  S e r  P ro  T r p  T y r  A l a  A s p  G l n  
7 4 0  7 4 5  7 5 0  
T h r  V a l  L e u  T y r  S e r  A r g  L y s  G l y  T r p  A s p  T h r  I l e  L y s  T y r  T h r  G l u  
7 5 5  7 6 0  7 6 5  
A l a  G l n  I l e  A l a  A l a  A s p  P r o  A s n  L e u  A r g  V a l  T y r  A r g  V a l  A l a  G l n  
7 7 0  7 7 5  7 8 0  
A r g  G l y  A r g  
7 8 5  
<210>  SEQ I D  NO 9 
<211>  LENGTH: 2 1  
<212>  TYPE: DNA 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: D e s c r i p t i o n  of A r t i f i c i a l  S e q u e n c e : f o r w a r d  
p r i m e r  corresponding t o  t h e  vec tor  sequence of pGFP 
p l a s m i d  ( A e q u o r e a  v i c t o r i a  green f l u o r e s c e n t  
p r o t e i n )  
<400>  SEQUENCE: 9 
ccgactggaa agcgggcagt g 
<210>  
<211>  
<212>  
<213>  
<220> 
<223>  
SEQ I D  NO 1 0  
LENGTH: 22  
TYPE: DNA 
ORGANISM: A r t i f i c i a l  S e q u e n c e  
FEATURE : 
OTHER INFORMATION: D e s c r i p t i o n  of A r t i f i c i a l  S e q u e n c e : r e v e r s e  
p r i m e r  corresponding t o  t h e  vec tor  sequence of pGFP 
p l a s m i d  ( A e q u o r e a  v i c t o r i a  green f l u o r e s c e n t  
p r o t e i n )  
2 1  
US 6,537,746 B2 
52 
- con t inued  
<400>  SEQUENCE: 1 0  
cggggctggc t t a a c t a t g c  gg 2 2  
< 2 1 0 >  SEQ I D  NO 11 
< 2 1 1 >  LENGTH: 4 
< 2 1 2 >  TYPE: PRT 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
< 2 2 1 >  NAME/KEY: MOD-RES 
<222> LOCATION: ( 1 )  
< 2 2 3 >  OTHER INFORMATION: X a a  = s u c c i n y l - A l a  
< 2 2 1 >  NAME/KEY: MOD-RES 
<222> LOCATION: ( 4 )  
< 2 2 3 >  OTHER INFORMATION: X a a  = P h e - p - n i t r o a n i l i d e  
< 2 2 3 >  OTHER INFORMATION: D e s c r i p t i o n  of A r t i f i c i a l  S e q u e n c e : B a c i l l u s  
s u b t i l i s  s u b t i l i s i n  E t h e r m o s t a b i l i t y  assay 
s u b s t r a t e  
<400>  SEQUENCE: 11 
X a a  A l a  P r o  X a a  
1 
2s 
What is claimed is: (c) screening or selecting the recombined polynucleotide 
1. A method for evolving a polynucleotide toward acqui- 
7. The method of claim 6, wherein the heteroduplexes are 
(a) incubating a population of parental polynucleotide 
variants having sufficient diversity that recombination 30 8. A method for evolving a polynucleotide toward acqui- 
between the parental polynucleotide variants can gen- 
erate more recombinated-polynucleotides than there (a) incubating first and second pools of parental poly- 
are parental polynucleotide variants under conditions to nucleotide variants having sufficient diversity that 
generate annealed polynucleotides comprising hetero- recombination between the parental polynucleotide 
duplexes; 35 variants can generate more recombined polynucle- 
(b) exposing the heteroduplexes to one or more enzymes otides than there are parental polynucleotide variants 
of a DNA repair system in vitro to convert the hetero- under conditions whereby a strand from any polynucle- 
duplexes to parental polynucleotide variants or recom- otide variant in the first pool can anneal with a strand 
bined polynucleotide variants; from any polynucleotide in the second pool to generate 
(c) screening or selecting the recombined polynucleotide 40 annealed polynucleotides comprising heteroduplexes; 
variants for the desired functional property. (b) exposing the heteroduplexes to a DNA repair system 
2. The method of claim 1, wherein the DNArepair system to convert the heteroduplexes to parental polynucle- 
comprises cellular extracts. otide variants or recombined polynucleotide variants; 
3. The method of claim 1, wherein the cells are bacterial (.) screening or selecting the recombined po~ynuc~eotide 
cells. 4s variants for the desired functional property. 
4. The method of claim 1 further comprising introducing 9, The method of claim 8, further comprising introducing 
the products of step (b) into cells. the heteroduplexes into cells, whereby the heteroduplexes 
5. The method of claim 4, wherein the introducing step are exposed to the DNA repair system of the cells in vivo. 
selects for transformed cells receiving recombinant poly- 10, The method of claim 9, wherein the annealed poly- 
nucleotides resulting from resolution of heteroduplexes in so nucleotides further comprise ~ o m o ~ u p ~ e x e s  and the intra- 
step (b) relative to transformed cells receiving PolYnucle- ducing step selects for transformed cells receiving hetero- 
otides resulting from resolution of homoduplexes in step (b). duplexes relative to transformed cells receiving 
6. A method for evolving a polynucleotide toward acqui- ~ o m o ~ u p ~ e x e s ,  
sition of a desired functional property, comprising 11. The method of claim 10, 6, or 5,  wherein a first 
(a) incubating a population of parental polynucleotide ss polynucleotide variant is provided as a component of a first 
vector, and a second polynucleotide variant is provided as a 
between the parental polynucleotide variants can gen- component of a second vector, and the method further 
crate more recombined polynucleotides than there are comprises converting the first and second vectors to linear- 
parental polynucleotide variants under conditions to ized forms in which the first and second polynucleotide 
generate annealed polynucleotides comprising hetero- 60 variants occur at opposite ends, whereby in the incubating 
duplexes; step single-stranded forms of the first linearized vector 
(b) introducing the annealed polynucleotides into cells reanneal with each other to form linear first vector, single- 
having a DNA repair system and propagating the cells stranded forms of the second linearized vector reanneal with 
under conditions to select for cells receiving heterodu- each other to form linear second vector, and single-stranded 
plexes relative to cells receiving homoduplexes, and to 65 linearized forms of the first and second vectors anneal with 
convert the heteroduplexes to parental polynucleotide each to form a circular heteroduplex bearing a nick in each 
variants or recombined polynucleotide variants; strand, and the introducing step selects for transformed cells 
variants for the desired functional property. 
exposed to the cellular DNA repair system in vitro. 
sition of a desired functional property, comprising 
sition of a desired functional property, comprising 
variants having sufficient diversity that recombination 
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receiving the circular heteroduplexes or recombinant poly- 25. The method of claim 1,6 or 8, wherein the population 
nucleotides derived therefrom relative to the linear first and of polynucleotides comprises variants generated by 
second vector. mutagenic PCK. 
12. The method of claim 11, wherein the first and second 26. The method of claim 1, 6 or 8, wherein the population 
vectors are converted to linearized forms by PCR. 5 of polynucleotide variants comprises variants generated by 
13. The method of claim 11, wherein the first and second site directed mutagenesis, 
vectors are converted to linearized forms by digestion with 27. The method of claim 1, 6 or 8, further comprising at 
first and second restriction enzymes. least partially demethylating the population of variant poly- 
14. The method of claim 10, 6 or 5, wherein the popula- nucleotides, 
tion of polynucleotides comprises first and second Poly- 10 28. The method of claim 27, whether the at least partially 
nucleotides provided in double stranded form, and the demethylating step is performed by PCR amplification of the 
method further comprises incorporating the fist and second population of variant polynucleotides. 
polynucleotides as components of first and second vectors, 29. The method of claim 27, wherein the at least partially 
whereby the first and second PolYn~cleotides OCCUPY OPPO- demethylating step is performed by amplification of the 
site ends of the first and second vectors, whereby in the 15 population of variant polynucleotides in host cells, 
incubating step single-stranded forms of the first linearized 30. The method of claim 29, wherein the host cells are 
vector reanneal with each other to form h e a r  first vector, defective in a gene encoding a methylase enzyme, 
single-stranded forms of the second linearized vector rean- 31, The method of claim 27, wherein the population of 
Deal with each other to form linear second vector, and variant polynucleotides are double stranded polynucleotides 
single-stranded linearized forms of the first and second 20 and only one strand of each polynucleotide is at least 
vectors anneal with each to form a circular heteroduplex partially demethylated, 
bearing a nick in each strand, and the introducing step 32. The method of claim 1,6 or 8, wherein the population 
selects for transformed cells receiving the circular hetero- of variant polynucleotide variants comprises at least 5 
duplexes or recombinant polynucleotides derived therefrom polynucleotides having at least 90% sequence identity with 
relative to the linear first and second vector. 
15. The method of claim 10, 6 or 5,  further comprising 33. The method of claim 1, 6 or 8, further comprising 
sealing nicks in the heteroduplexes to form covalently- isolating a screened recombinant variant. 
closed circular heteroduplexes before the introducing step. 34. The method of claim 33, further comprising express- 
16. The method of claim 1, 6 or 8, wherein the Population ing a screened recombinant variant to produce a recombi- 
of polynucleotide variants are provided in double stranded 30 nant protein, 
form, and the method further comprising converting the 35, The method of claim 34, further comprising formu- 
double stranded polynucleotides to single stranded Poly- lating the recombinant protein with a carrier to form a 
nucleotides before the annealing step. pharmaceutical composition. 
17. The method of claim 1, 6 or 8 wherein the converting 36, The method of claim 1, 6 or 8, wherein the polynucle- 
step comprises: 35 otide variants encode enzymes selected from the group 
conducting asymmetric amplification of the first and consisting of proteases, lipases, amylases, cutinases, 
second double stranded polynucleotide variants to cellulases, amylases, oxidases, peroxidases and phytases. 
amplify a first strand of the first polynucleotide variant, 37. The method of claim 1,6 or 8, wherein the polynucle- 
and a second strand of the second polynucleotide otide variants encode a polypeptide selected from the group 
variant, whereby the first and second strands anneal in 40 consisting of insulin, ACTH, glucagon, somatostatin, 
the incubating step to form a heteroduplex. somatotropin, thymosin, parathyroid hormone, pigmentary 
18. The method of claim 17, wherein the first and second hormones, somatomedin, erythropoietin, luteinizing 
hormone, chorionic gonadotropin, hyperthalnic releasing 
factors, antidiuretic hormones, thyroid stimulating hormone, 
38. The method of claim 1,6 or 8, wherein the polynucle- 
otide variants encode a plurality of enzymes forming a 
metabolic pathway. 
39. The method of claim 1,6 or 8, wherein the polynucle- 
40. The method of claim 39, wherein the functional 
property is an enzymatic activity. 
41. The method of claim 1,6 or 8, wherein the at least two 
polynucleotide variants differ at between 0.1-25% of posi- 
42. The method of claim 1, 6 or 8, wherein the functional 
25 one another. 
double-stranded polynucleotide variants are provided in 
vector-free form, and the method further comprises incor- 
porating the heteroduplex into a vector. 
19. The method of claim 18, wherein the first and second 
polynucleotides are from chromosomal DNA. 
20. The method of claim 1, 6 or 8, further comprising 
repeating steps (a)<c) whereby the incubating step in a 
subsequent cycle is performed on recombinant variants from 50 otide variants are in concatemeric form. 
a previous cycle. 
otide variants encode a polypeptide. 
of polynucleotide variants comprises at least 20 variants. 
of polynucleotide variants are at least 10 kb in length. 
45 relaxin, interferon, thrombopoietin (TPO), and prolactin. 
21. The method of claim 1, 6 or 8, wherein the polynucle- 
22. The method of claim 1, 6 or 8, wherein the population 
23. The method of claim 1, 6 or 8, wherein the population 
24. The method of claim 1, 6 or 8, wherein the population 
55 tions. 
property is an enzymatic activity. 
of polynucleotide variants comprises natural variants. * * * * *  
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